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PART I

PARTIAL AMINO ACID SEQUENCE OF RAT SKIN TRYPTASE

CHAPTER I
INTRODUCTION

Tryptase has been isolated and partially characterized
from a variety of species including rat, dog, bovine, and
human.

The potential roles of tryptase in pathogenesis of

different diseases have attracted close attention of many
investigators in recent years.
Tryptase is a serine protease which hydrolyses peptide
bonds on the C-terminal side of either arginine or lysine.
However, tryptase does not exhibit general proteinase activity
and has a stronger subsite preference and a higher degree of
selectivity

toward

model

substrates

than

trypsin.

Recently, amino acid sequences of tryptase from mouse,
dog, and human have been deduced from the nucleotide sequence
of cDNA cloned from mast cell cDNA libraries.

The sequences

show some basic structural differences between tryptase and
trypsin.

In this lab, a tryptase has been purified from rat

skin and intensively characterized.

The rat skin tryptase

shows similar inhibitor and substrate specificity to other
tryptases.

However, rat skin tryptase also appears to have

its unique chemical properties.
In this study, partial amino acid sequences of rat skin
2

3

tryptase have been determined using the Edman procedure and
compared with other tryptase sequences.

The results have

revealed some profound structural differences and some common
features among tryptases.

These interesting observations

suggest that specific amino acid residues responsible for the
functional specificity of tryptases can be identified.

The

information obtained from this study can be very helpful in
designing fulture experiments to explore the structure and
function relation of tryptases.

4

CHAPTER II
LITERATURE REVIEW

1. Biological Function
Tryptase is a trypsin-like serine proteinase found in
secretory granules of mast cells

(Schwartz et §.!..

1981) .

Although the precise function of tryptase in vivo is not
clear, many possible biological and

pathological roles have

been postulated based on a large number of in vitro studies.
There is evidance that tryptase may have anticoagulant
effects.

Tryptase can hydrolyze fibrinogen and inactivate the

thrombin-induced
1985) .
(HMWK)

clotting of

fibrinogen

(Schwartz

et

al.

Tryptase also degrades high molecular weight kininogen
(Maier

prekallikrein

et

al.

1983).

HMWK

to kallikrein which

is

then

known
can

to

convert

initiate

the

intrinsic coagulation pathway by activating factor XIIa.

By

hydrolyzing HMWK, tryptase rapidly inactivates HMWK-dependent
coagulation activity.

The role of tryptase in the conversion

of low molecular weight kininogen to bradykinin, a potent
vasodilator, is controversial (Schwartz et al. 1986, Proud et
al. 1988).

Although a systematic defect of coagulation does

not usually occur, the anticoagulant effect may be important
in some local tissue environments such as in mucosa, skin, and
lung (Schwartz 1990) .

However, tryptase was shown to convert

prothrombin to thrombin (Kido et al. 1985).

The potential

5

biological role of this activity remains to be explained.
Tryptase has been suspected to be a mediator of airway
smooth muscle hyperresponsiviness that is characteristic of
asthmatic individuals {Caughey 1989, Sekizawa et al. 1989).
The

evidence

showed

that

dog

bronchial

smooth

contraction was prevented by a tryptase inhibitor.

muscle

Vasoactive

intestinal peptide {VIP) is a potent relaxant of various types
of smooth muscles {Matsuzaki _g.t_ al. 1980, Said 1987).
histidine-methionine {PHM)

Peptide

is also a potent bronchodilating

peptide that co-exists with VIP and regulates blood flow and
bronchial smooth muscle tone {Itoh et al. 1983, Lundberg et
gl. 1984, Palmer et al. 1986, Linder et al. 1987).

Substance

P

a

{SP) ,

on

the

other

hand,

is

believed

to

be

potent

bronchoconstrictor {Lundberg et al. 1983) which can cause mast
cell degranulation in lung {Barrett et al. 1986) and regulate
the vasodilator activity of calcitonin gene-related peptide
{CGRP), a potent vasodilator in skin {Brain 1988) and lung
{Palmer~

al.

1987).

Tryptase selectively hydrolyzed the

bronchodilation peptides

VIP,

PHM,

bronchoconstriciton peptide SP

may

contribute

to

CGRP but

{Caughey et al.

Caughey 1990, Walls et al. 1992).
tryptase

and

not

the

1988, Tam &

The evidence suggests that

smooth muscle

contraction

by

regulating the activity of the neuropeptides.
A potential

role

for

tryptase

in peptide prohormone

processing has been proposed {Cromlish et al. 1987, Proctor et
al. 1991).

Adrenocorticotropic hormone {ACTH) is a pituitary

6

hormone which regulates the growth and function of the adrenal
cortex.

Human pituitary tryptase selectively cleaves the

ATCH(l-39)

to

form

ACTH(l-15)

and

ACTH(16-39).

Atrial

natriuretic factor (ANF) is a peptide hormone produced by the
heart (Debold 1985) which promotes a reduction of blood volume
and pressure and causes a generalized vasodilation.

The pro-

ANF, which consists of 126 amino acids, can be converted to
active ANF by human and bovine tryptase.
Processing of certain enzymes and proteins suggests other
potential roles of tryptase.

Tryptase was shown to cleave

complement protein C3 to generate C3a, a chemotactic factor,
in vitro (Schwartz et al. 1983).
A

role

for

tryptase

in

the

degradation

extracellular matrix has been proposed.

of

human

Rapid activation of

purified prostromelysin or pro-matrix metalloprotease 3 (MMP3)

can

result

from

incubation

with

physiological

concentrations of tryptase (Gruber et al. 1988, 1989).

The

active stromelysin in turn converts the procollagenase to
active collagenase
Active

(Vater et al.

stromelysin

extracellular
collagen,

is

matrix

f ibronectin,

also

capable

components
laminin,

(Chin et al. 1985, Okada,

§.t.

1983,

such

Ito et al.

1988).

of

degrading

as

type

gelatin,

IV

other
and

IX

and proteoglycans

al. 1986, Okada et al. 1989).

The evidence indicates that tryptase may play an important
role in connective tissue turnover such as in the case of
rheumatoid arthritis and various fibrotic conditions.

7

Tryptase was found to hydrolyze the DNA binding protein
histone Hl effectively.

The observation suggested a possible

role for tryptase in the organization of DNA during cell
turnover {Harvima et g,,l. 1989}.

In a recent study {Ruess

gt.

g,l. 1991}, tryptase was implicated as a potent mitogen which

strongly stimulates DNA synthesis and cell growth in cultured
rat fibroblast and chinese hamster lung cell lines.
Tryptase is stored in an active form in mast cells and is
released
vassimon

upon
&

mast

cell

Rothschild 1990}.

degranulation
As

{Schwartz

1990b,

a unique marker for the human

mast cell {Craig & Schwartz 1989}, tryptase has been used as
a useful clinical indicator of mast cell activation {Matsson
et

al.

1991} .

The

specific

cellular

localization,

the

abundance in human tissues, and the stability in serum make
tryptase a preferred mast cell activation indicator over
histamine which has been used traditionally in determination
of anaphylaxis.

Histamine can be secreted from not only mast

cells, but also from basophil.

The histamine level in serum

declines to baseline within 15-60 minutes while tryptase has
a half life in the circulation of about 2 hours {Schwartz et
al. 1989}.

2. Chemical And Physical Properties
Information regarding tryptase has accumulated rapidly in
the past few years.

Shortly after the partial purification of

a neutral proteinase with characteristics of a tryptase from

8

human uterine

cervix

(Ito t t al.

1980),

a

tryptase was

purified and characterized from human pulmonary mast cells
(Schwartz

~

.sY.,. 1981) .

Since then, human tryptase has been

purified from lung (Smith .e.t. al. 1984), pituitary (Cromlish .e.t.
gl. 1987), skin (Harvima

~al.

1988), as well as from a human

mast cell line established from peripheral blood of a patient
with leukemia

(Butterfield~

al. 1990).

Non-human tryptases

have been purified from rat peritoneal cavity mast cells (Kido
g.t. gl.

1985, Lagunoff .e.t. gl. 1991) ,

rat skin

(Braganza

&

Simmons 1991) , dog mastocytoma cells originally isolated from
skin tumors (Caughey et al. 1987), and mast cells from bovine
liver capsula (Fiorucci et al. 1992).
A total of seven cDNAs and two genes for tryptases have
been cloned and sequenced.

The first cDNA for tryptase was

obtained from a dog mastocytoma cDNA library (Vanderslice et
al. 1989).

Two cDNAs for human lung tryptases were cloned and

sequenced from the same human lung mast cell cDNA library
(Miller~

al. 1989, 1990).

The two lung tryptases exhibited

90%' amino acid identity and were named O!-tryptase and {Jtryptase.

After screening a human skin cDNA library, three

skin cDNAs for tryptases with over 90%' identities among them
were sequenced and called human skin tryptase-1, -2, and -3
(Vanderslice

~

al. 1990).

to human lung {J-tryptase.

Human skin tryptase-2 is identical
The gene for human skin tryptase-1

was cloned and sequenced using the human skin tryptase-2 cDNA
to screen the genomic library.

In mouse, where no tryptase

9

has been purified, two cDNAs and a gene for tryptase were
identified

from mouse
~

protease-6 {Reynolds

mast

cell

lines.

Mouse mast

cell

s.J... 1991) is identical to mouse mast

cell tryptase-1 which has 71% of amino acid identity to mouse
mast cell tryptase-2 {Chu 1990).

The cDNA sequences provide

us with a source for the basic amino acid sequence information
about tryptases.
Tryptase

is

a

trypsin-like

serine

protease

that

hydrolyzes peptide bonds on the carboxyl side of an arginine
or lysine residue.

However, tryptase has a more restricted

substrate specificity than trypsin.
around the arginine or lysine

Amino acid residues

residues

of the substrate

greatly affect the rate of substrate hydrolysis by tryptase
{Schwartz et al. 1981, Tanaka et al. 1983, Kido et al. 1985,
Smith et al. 1984, Cromlish et al. 1987, Braganza & Simmons
19 91) .

Tryptase is inhibited by the serine protease inhibitor

di-isopropylfluorophosphate {DFP), trypsin inhibitors such as
N-tosyl-L-lysine chloromethylketone {TLCK), and the natural
microbial-derived inhibitors leupeptin and antipain.

Other

trypsin inhibitors such as lima bean trypsin inhibitor {LBTI) ,
soybean trypsin inhibitor {SBTI) , and ovomucoid have little or
no effect on tryptases. Chymostatin, N-tosyl-L-phenylalanine
chloromethylketone

(TPCK) ,

pepstatin,

and ethylenediamine-

tetraacetic acid {EDTA) do not inhibit the enzyme.
Al though there are many common properties among tryptases
from different sources, they exhibit different responses to

10
certain

inhibitors.

Rat

skin

tryptase,

inhibited by aprotinin {Trasylol)

for

example,

{Braganza & Simmons 1991)

while human lung tryptase is not {Smith et al. 1984).
thiol-group

inhibitor,

is

p-chloromercuribenzoate

The

{PCMB),

inhibits human pituitary tryptase but not human lung, human
uterine

cervix,

rat,

or dog

While human skin

tryptase.

tryptase and human 1 ung tryptase are inhibited by benzamidine,
human peripheral blood mast cell tryptase is insensitive to
the inhibitor.
to

Rat peritoneal mast cell tryptase is sensitive

~-1-antitrypsin

which,

on

the

other hand,

has

little

inhibitory effect on rat skin tryptase and other purified
tryptases.

Rat peritoneal mast cell tryptase was reported to

be associated with a unique endogenous Kunitz-type trypsin
inhibitor

{or basic pancreatic trypsin inhibitor),

trypstatin {Kido et al. 1985, 1988) .
has

been detected

in

other

called

No associated trypstatin

tryptases

including

rat

skin

tryptase.
The reported molecular weight of native tryptases varies
from 110,000 to 150,000 depending on the source of the enzyme.
Tryptase is a tetra.mer with subunits in the
range

of

30, 000

to

38, 000.

Variation

molecular weight
of

the

reported

molecular weights may be due to the extent of glycosylation of
the

tryptase.

Tryptase

deglycosylation enzyme)

treated

had a

with

N-Glycanase

{a

subunit molecular weight of

32,400 for human pituitary tryptase and about 27,000 for rat
skin tryptase.

Putative glycosylation sites detected from the

11
cDNA-deduced amino acid sequences

suggest

that different

tryptases may have different numbers of glycosylation sites.
Functionally, tryptase share a great deal of their conunon
physical and chemical properties and at the same time exhibit
a substantial degree of variations among them.

Structurally,

despite of the high homology among tryptases, they also reveal
a great extent of diversity in the amino acid sequences.

The

functional and structural properties of a group of similar
enzymes will provide the fundamental information necessary for
correlating

enzyme

functions

to

their

structures.

For

example, chymotrypsin, trypsin and elastase are members of the
serine protease family.

Their functional properties have been

well related to their structural features.

Serine 189 in the

substrate binding pocket contributes to the specificity of
chymotrypsin which requires an aromatic or bulky side chain
such as tyrosine, phenylalanine, tryptophan and methionine in
the P1 site of the substrate.

The same position occupied by

aspartate instead results in a totally different substrate
specificity in trypsin.

The acidic aspartate residue in

trypsin limits its binding only to substrates with basic
residues such as lysine and arginine.

In elastase,

the

binding pocket is blocked because of the replacement of two
glycine residues in the substrate binding site by two bulkier
valine and threonine residues.

The structural feature is

reflected by the functional specificity of elastase to smaller
residues such as alanine, glycine, and serine.

12
In order to draw a correct correlation, the structure, or
amino acid sequence, must be the sequence of the functional
enzyme characterized.

The data gathered up to date are not

sufficient for the correlation.

Human skin tryptase-1 cDNA

was matched to tryptase purified from human lung based on the
24 amino acids at the N-terminal of the characterized enzyme.
However, human skin tryptase-2 cDNA also has 24 identical
amino acids at the N- terminal.

Thus, the amino acid sequences

derived from the cDNAs have not been precisely assigned to any
specific

human

tryptase

purified

and

characterized.

Sequencing through the Edman procedure can provide direct
correlation of the function of a specific tryptase with its
structural properties.

Undoubtedly, further exploration of

the structural and functional properties of tryptase will lead
to a deeper understanding of the role of tryptase in nature
and have a great pharmacological significance in the near
future.

3.

Purpose Of The Project
The main purpose of this project is to investigate the

potential structure and function relationship among tryptases.
The biological significance of tryptase can be appreciated as
a specific component of mast cell granules.

Tryptase purified

from different sources have demonstrated their common and
unique chemical and amino acid sequence properties as seen in
the review section above.

The observations raise our interest
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in preparing to investigate the relation between tryptase
functions and their structural features.

In order to draw a

correct correlation, it is very important to know that the
primary

structure

characterized.

obtained

belongs

to

the

enzyme

To achieve this goal, I tried to obtain as

much sequence as possible from rat skin tryptase using the
Edman procedure.
important

The sequence obtained here provides some

preliminary

information

about

the

structural

features of rat skin tryptase and serves as a good starting
point for continuing the project in the future.
Specifically, a large amount of tryptase was purified
from rat skin.

The purity of tryptase was verified by SDS-

PAGE and reversed-phase HPLC.

The unstable cystine residues

in tryptase were converted to stable S-carboxymethylcysteine
through an alkylation procedure before the Edman reaction.
The

alkylated

fragmented.

proteins
The

were

resulting

enzymatically
peptides

were

or

chemically

subjected

to

different types of HPLC chromatography including the use of
gel permeation and reversed-phase columns.

The purified

peptides were sequenced by the Edman procedure using an
automated sequencer. Rat skin tryptase peptides were compared
with other tryptase sequences.
interesting observations.

The study exhibited some very

CHAPTER III
MATERIALS AND METHODS
A. Materials
Rat skin (Sprague-Dawley), was obtained from other labs
or Pel-Freez Biologicals, Rogers, Arkansa.

Na~P04 ,

NaHP04 ,

NaCl, ethanol, glycerol, acetic acid, and glutaraldehyde were
from Mallinckrodt, St. Louis, MO.
acid

(EDTA),

Ethylenediaminetetraacetic

agarose-glycyl-glycyl-p-aminobenzamidine

gel

(PAB), benzamidine.HCl, concanavalin A-agarose gel (Con A),
methyl-D-mannoside,

NaN3 ,

benzoyl-L-arginine

ethyl

~-

ester

{BAEE), iodoacetic acid, acetonitrile, trifluoroacetic acid,
bovine serum albumin fraction V (BSA),

and Mark VI protein

molecular weight standards were from Sigma Chem.
Louis, MO.

from Schwarz Mann Biotech.
MA.

Amrnomium sulfate was obtained

Div.

(3H)iodoacetic

Arlington Heights,
Research

St.

Bradford Reagent for protein assay was from Bio-

Rad Laboratories, Richmond, CA.

Camgridge,

Co.,

Labs,

IL.

of

ICN Biomedicals,

acid

was

from

Inc. ,

Amersham,

Dialysis tubing was from Bethesda

Gaithershurg,

MD.

Centricon-30

microconcentrator units were from Amicon Division, W.R. Grace

& Co., Danvers, MA.
strips

were

from

Homogeneous gels
Pharmacia,.

14

(12%)

and SOS buffer

N-Glycanase

cloned

from

15
£lavobacterium meningosepticum and expressed in .IL.. Coli. was
obtained

from

Genzyme.

Trypsin

was

from

Serva,

NJ.

Lysylendopeptidase C was from Wako Fine Chem., Japan.

B. Methods
1. Purification Of Rat Skin Tryptase
Sprague-Dawley

rats

were

decapitated and

removed and stored at -20 °C until use.

the

skins

Alternatively, rat

skin was obtained from Pel - Freez Biological, Rogers, Arkansas.
The fur was clipped away as close as possible to the epidermis
using an Ostar Professional Animal Grooming Clipper, Model AS, with a No. 80, Size 40 blade.

The fat layer and the thin

cutaneous muscle {Hebel & Stromberg 1976) were scraped off
using a stainless steel blade.

The skins were then rinsed

well in tap water followed by distilled water and minced in a
Universal No. 3 meat grinder through two cycles.
purification, about 400 g of skin were used.

For each

All subsequent

steps were carried out at 4 °C unless otherwise indicated.
The minced skin was weighed and homogenized at a 1: 9
{w/v) ratio of the homogenization buff er {Appendix A) using a
Waring blender, model PB-5, at full speed for 6-8 times with
20 second rest intervals.

The homogenate was filtered through

a nylon mesh in a Buchner funnel under vacuum.

The volume of

the filtrate was recorded and 1 ml was saved for analysis.
The filtrate was brought to 25% {NH4 ) 2804 saturation by
adding 139 g of the sal t/l.

The solution was allowed to
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equilibrate for 4-6 hours.

After centrifugation at 13,700 xg

for 15 minutes in a Sorvall GSA rotor at 4 °C, the supernatant
was brought to 80% {NH4 ) 2804 by adding 361. 5 g of the salt/l
quickly

{Taylor 1953).

overnight.

The solution was allowed to sit

The solution was then centrifuged at 13, 700 xg for

15 minutes.

The pellet was resuspended in 100 ml of the

dialysis buff er {Appendix A) and dialyzed against two changes
of 6 1 of the dialysis buffer overnight.
The dialyzed fraction was centrifuged at 23,700 xg in a
Sorvall SS-34 rotor for 15 minutes and applied to an agaroseglycyl-glycyl-p-aminobenzamidine {PAB) affinity column {1.5 x
20 cm) equilibrated with the dialysis buffer at a flow rate of
25 ml/h at room temperature.

The sample itself was kept on

ice during application to the column.

The column was then

washed with 50 ml of the PAB equilibration buffer {Appendix A)
at room temperature and then moved to 4 °C for 1 hour before
washing again with another 25 ml of the same buffer.

A

concanavalin A-agarose {Con-A) column (1 x 10 cm) , previously
washed with 20 ml of the Con-A activation buffer {see Appendix
A) followed by PAB equilibration buffer, was connected to the
PAB column.

The enzyme was eluted from the PAB column to the

Con-A column by applying 40 ml of the PAB elution buffer
{Appendix A)

at

a

flow

rate

of

10

ml/h.

After

the

application, the Con-A column was disconnected from the PAB
column and washed with 10 ml of the PAB equilibration buffer.
The enzyme was washed off the Con-A column with the Con-A
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elution buffer
fractions were

(Appendix A)

at

a

rate

of

5

ml/h.

The

collected in 1 ml/tube and assayed for enzyme

activity. Those fractions containing activity were pooled and
concentrated

using

units (Am.icon).
2 ml

of

several

Centricon-30

microconcentrator

After concentrating each sample to 50-100 µl,

the dialysis buffer was

added

to

each unit

concentrated until 50-100 µl was left in each unit.
was repeated once.

This step

Each unit was then rinsed twice with 100

µl of the dialysis buffer.

The final fractions were pooled

together and stored at 4 °C.
PAB wash buffer

and

(Appendix A)

The PAB column was washed with
followed by PAB equilibration

buffer at room temperature and stored at 4 °C.

The Con-A

column was washed with the Con-A wash buffer (Appendix A) and
stored in Con-A activation buffer at 4 °C.
Enzyme activity was measured by monitoring the hydrolysis
of benzoyl-L-arginine ethyl ester (BAEE) at 253 nm (Schwert &
Takenaka 1955).

The sample cuvette contained 440 µl of the

assay buffer (Appendix A), 10 µl of the sample, and 50 µl 10
mM BAEE.

The reference cuvette contained 450 µl of the assay

buffer and 50 µl of the 10 mM BAEE. The initial rate

(0-5

minutes) was measured in a Gilford Response Spectrophotometer.
One unit of activity was defined as 1 µmole

of substrate

hydrolysed per minute. Specific activity is defined as unit
activity per mg of protein and calculated according to the
following formula:
Specific Activity=

(~ 3,min)

(0.5 ml)/(0.9 x mg protein/ml x
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ml}
where A.Az,s31min is

the rate of BAEE hydrolysis,

O. 9

is the

absorbance change for total cleavage of BAEE in the cuvette,
mg protein/ml is the protein concentration of the sample, and

ml is the volume of the sample used in the assay.
Protein concentration was determined using the microassay
procedure from Bio-Rad (Bradford 1976} .

Bovine serum albumin

fraction V from Sigma was used as a standard.

The standard

curve and the sample protein concentration were obtained at

As9s on the Gilford Response Spectrophotometer.
The purity of the protein was checked by sodium dodecyl
sulfate polyacrylamide gel electrophoresis

(SOS PAGE}

and

reverse phase high performance liquid chromatography (HPLC}.

2. SOS-PAGE
SOS-PAGE was performed under reducing conditions on a
PhastSystem from Pharmacia according to the manufacturer's
manual.

Protein samples were concentrated in a Centricon-30

unit to 50 µg/ml or higher.

The recovery of tryptase from the

Centricon-30 was above 90% in water.

The samples were mixed

with the sample buffer (Appendix B} at a 1:1 ratio and boiled
for 5 minutes before application of the samples to the gels.
PhastGel homogeneous 12. 5 or PhastGel gradient 10-15 gels were
used for the separation.

The samples were applied to the gel

using size 6/4 sample applicators and separated with the
buff er strips using the following program:

sos
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SEP. PROGRAM 1
sample Application Down At

1.2

0 vh

sample Application

1.3

0 vh

Up At

Sep. 1.1

250 v

10 mA

3 w

15

Sep. 1.2

250 v

1 mA

3 w

15

Sep. 1.3

250 v

10 mA

3 w

15

oc
oc
oc

1 vh
1 vh
80 vh

The gel was stained with silver in the development unit using
the following program:
DEV. PROGRAM 1

Steps

Solutions

I n -

Ou t -

Time

Temp .

Port

Port

min

oc

1

50% Eth, 10% HAc

2

0

2

so

2

10% Eth,

5% HAc

3

0

2

50

3

10% Eth,

5% HAc

3

0

4

50

4

Glutaraldehyde

4

0

6

50

5

10% Eth,

5% HAc

3

0

3

50

6

10% Eth,

5% HAc

3

0

5

50

7

MQ Water

5

0

2

50

8

MQ Water

5

0

2

50

9

Silver Nitrate

6

0

13

40

10

MQ Water

5

0

0.5

30

11

MQ Water

5

0

0.5

30

12

Developer

7

0

0.5

30

13

Developer

7

0

4

30

20
14

5% HAc

8

0

2

50

15

6% Glycerol

9

0

3

50

Eth stands for ethanol, MQ water for milli Q water, and HAc
for glacial acetic acid.
Appendix B.

The solutions used are given in

Protein standards from Sigma included bovine

albumin with a molecular weight of 66,000, ovalbumin (43,000},
pepsin

(34,700},

trypsinogen

(18,400}, and lysozyme (14,300}.

(24,000},

P-lactoglobulin

The relative mobility (Rf}

of a protein was determined according to the formula: Rf
Distance
migration.
known

of

protein

migration/Distance

tracking

dye

The Rf values (abscissa} were plotted against the

molecular weights

paper.

of

=

The

molecular

(ordinate}

on

a

weight

a

sample

of

semi-logarithmic
was

either

extrapolated from the determined sample Rf value in a standard
curve or calculated from the regression equation derived from
the logarithmic values of the molecular weight and the Rf
values of the protein standards.

A standard was prepared for

each gel.

3. Reversed-Phase HPLC
A Varian model 5500 HPLC system was used.

The protein

and peptides were separated based on their hydrophobicities
using butyl- (C4}, octyl-

(CS}, and octadecyl- (C18} columns

from Rainin Instrument Co.,

Inc., Woburn, MA.

The samples

were dissolved in 6 M quanidine-hydrochloride solution.

The
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mobile phase was delivered as a linear gradient of increasing
acetonitrile in O.lt trifluoroacetic acid (TFA) at O.S ml/min.
solution A contains 0.1% of TFA in water. Solution B contains
o.1t of TFA in acetonitrile.

A typical separation program is

shown as the following:

Solvent B

Solvent A

Time

(%)

(min)

Flow

Rate

(ml/min)

(%)

0

100

0

o.s

60

40

60

o.s

62

0

100

o.s

64

100

0

o.s

Protein peaks were detected at 206 nm using a UV mornitor and
collected into plastic tubes.

The collected fractions were

dried by speed vacuum centrifugation.

4. Enzymatic Deglycosylation Of Tryptase
Purified tryptase was concentrated to 2 mg/ml in MQ water
using a Centricon-30 unit.
boiling for
containing

Tryptase (3.2 µg) was denatured by

s minutes in 20 µl of 100
so

mM

mM

Tris-HCl, pH 8,

P-mercaptoethanol and O. st SDS.

To the
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denatured sample was added 5 µl of 7.5% Nonidet P-40 followed
by 5 µl {1.25 units) of recombinant peptide-N-Glycosidase F
{N-Glycanase)

in a buffer containing 50% glycerol,

NaCl, 1 mM EDTA and 80 mM sodium phosphate.
incubated at 37

°c.

O .15 M

The reaction was

After 20 hours, an additional 1.5 µl {0.4

units) of N-Glycanase was added and the reaction was allowed
to continue overnight.
for 5 minutes.
Glycanase was
buffer.

The reaction was terminated by boiling

In a parallel control experiment,

the N-

replaced by the same volume of the enzyme

In another control experiment, the reaction contained

all of the components except tryptase which allowed detection
of any N-Glycanase on a gel if it occured.

The samples were

subjected to SDS-PAGE along with Sigma VI molecular weight
standards.

Gels were developed with silver stain using the

Pharmacia PhastSystem as described above.

5. Alkylation of Tryptase

Since cysteine residues are subject to autoxidation, they
must

be

converted

sequencing.
convert

the

to

more

stable

derivatives

before

Iodoacetic acid was used to radiolabel and
cysteine

residues

to

a

stable

s-

carboxymethylcysteine {Allen 1986) .
The purified tryptase {about 200 µg) was dissolved in a
solution containing 6 M quanidine hydrochloride by adding 0.7
g of the salt and 400 µl of a Tris-HCl buffer {Appendix C) and
then vortexing well.

The protein was reduced by dissolving
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o.2 mg of DTT in the solution followed by incubation at room

A 50 µl solution of [ 3H]-iodo-acetic

temperature for 1 hour.
acid

(Appendix C}

was added.

The solution was capped and

sealed in the dark at room temperature for 30 minutes.

The

reaction was driven to completion by addition of 4. 8 mg of DTT
to the solution followed by incubation in the dark at room
temperature
solution

for

1

hour.

(Appendix C}

Non-radioactive

was

then added

iodoacetic acid

to

the mixture

incubated for another 30 minutes in the dark.
reaction was

terminated by addition of

and

Finally, the

60 µl

of

6 N HCl

solution (Appendix C}.
The unincorperated iodoacetic acid and other salts were
removed from the alkylated enzyme using a 1 x 30 cm Sephadex
G-25-80 column.

The column was equilibrated in either an

ammonium bicarbonate buffer

(Appendix C}

or a formic acid

solution (Appendix C} depending on the digestion method to be
used.

The column was calibrated using 1 or 5 mg of bovine

serum albumin at a flow rate of 30 ml/h.
collected

in about

1 ml/tube.

protein were detected at 280 nm.

The fractions were

Fractions

containing

After the calibration, the

alkylation mixture was applied onto the column.
collected were
presence

of

the

counted
sample

for
and

the

radioactivity
then

dried

to
by

The fractions
confirm
speed

the

vacuum

centrifugation before chemical or enzymatic fragmentation.

6. Enzymatic Cleavage Of Tryptase
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Trypsin was used to catalyze the hydrolysis of lysyl and
arginyl peptide bonds in the alkylated tryptase.

Tryptic

digestion was conducted at a protein:trypsin molar ratio of
100: 1 in a buffer containing O .1 M NH.HC03 and O .1 mM CaC1 2 , pH

e.

About 40 µg of the alkylated tryptase was mixed with 0.4

µl of the 1 mg/ml trypsin in 0.1 mM HCl, 10 µl of 1 mM CaC1 2 ,
and 90 µl of 0.1 M NH4HC03 , pH 8.

The reaction was allowed to

continue at 37 °C for 16 hours and stopped by speed vacuum
centrifugation.
Lysylendopeptidase-C (Lys-C) was used to catalyze the
hydrolysis of lysyl peptide bonds in tryptase.

The reaction

mixture contained 100 µl of 50 mM Tris-HCl, pH 9, 1 µg of LysC and 100 µg of the alkylated tryptase.

The reaction was

allowed to continue at 37 °C for 6 hours and stopped by speed
vacuum centrifugation.

7. Separation And Purification Of Peptides
Digestion of tryptase was first evaluated by running a
small amount of the sample on 12% SDS-PAGE.

Then the peptides

were separated and purified by HPLC.
Separation of the tryptic peptides was carried out using
a C18 column.

The sample was dissolved in 6 M quanidine-HCl

solution and injected into the HPLC.

The mobile phase

contained a linear gradient of increasing acetonitrile from 0%
to 60% in 60 minutes.

The peaks from the separation were

collected in separate tubes, labeled and centrifuged under
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vacuum.

Some peaks which had overlap shoulders were separated

again using a CS column.

The acetonitrile concentration was

increased from 10% to 20% over 20 minutes.
Peptides from the Lys-C digest were separated using a gel
permeation column {Bio-Sil TSK-125 from Bio-Rad).
were

dissolved

in

6

M quanidine-HCl.

The

Samples

mobile

phase

contained 6 M quanidine-HCl and 10 mM potassium phosphate, pH
6.

Peptide peaks were collected in separate plastic tubes.

Peptides separated by the gel permeation column were subject
to a second purification using a C4 hydrophobic column.
acetonitrile gradient was
minutes.

The

fractions

increased from 0%
were

dried

by

to 60%
speed

The
in 30

vacuum

centrifugation.

8. Amino Acid Sequence Determination
Reverse-phase HPLC purified peptides were sequenced by
the Edman procedure using an ABI 477A automated sequencer
equipped with on-line PTH analyzer 120A.

CHAPTER IV
RESULTS

1. Purification Of. Rat Skin Tryptase
A large amount of tryptase had to be purified from rat
skin in order to satisfy the requirements of the project.
total

of

2~000

purifications.

µg

of

tryptase

was

isolated

A

from
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A typical purification result is shown in

Table 1.
In the purification procedure, a high salt concentration
(O.S M NaCl}

from rat skin.

was used to facilitate extraction of tryptase
Precipitation of protein in the crude extract

at 25- 80% ammonium sulfate saturation removed large amounts of
contaminating

proteins.

As

observed

in

most

of

the

purifications, the enzyme activity measured at this step was
lower than expected.
of

other

It may be due to either the elimination

non-tryptase

BABE

activity

in

this

step

or

interference of residual ammonium sulfate after an overnight
dialysis.

The salt did not significantly interfere with the

binding of tryptase to the PAB column at room temperature.
In one purification, the fat and the cutaneous muscle
layers associated with the skin were not removed prior to
homogenization to see if this affected the ability to obtain
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Fractions

Volume
(ml)

Prat.Cone. Tot.Prat. Act.
(mg)
(mg/ml)
(U/ml)

Sp.Act.
(U/mg)

Tel.Act.

Yield
(Ut)

Pur.Fact.
(Fold)

(U)
Crude
Extract
(NH4) 2S04
25-80%'
PAB/Con A
Columns
Table 1.

1530

2.23

3412

0.085

0.038

130.1

100

95

9.81

932

0.216

0.022

20.5

16

13.2

10

2.7

0.032

0.085

4.943

154

1
0.6
4053

Purification Of Rat Skin Tryptase.

l:V
...J
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purifed enzyme.

The presence of components from the fat and

muscle layers seriously decreased the flow rate of the PAB
affinity column step.

In the subsequent purifications, these

layers were removed as in the original published procedure.
The PAB/Con-A step gave a purification factor of about 4,000fold and yielded a recovery of BAEE hydrolyzing activity of
about 10%.

The result is consistant with the previous report

in which the calculated recovery based on cleavage of the
specific substrate D-Ile-Pro-Arg-pNA was 35%, giving an enzyme
preparation purified 14,000 fold {Braganza & Simmons 1992).
A typical preparation from about 300-400 g skin tissue yielded
about 80-90 µg of purified tryptase.

The procedure was used

successfully a few times to obtain about 150 µg of highly
purified tryptase in one purification from a larger amount of
skin.

In one isolation, over 230 µg of tryptase was purified

using the procedure.

However, scaling up this procedure for

the preparation of larger amounts of tryptase was difficult.
The purity of tryptase was checked with SDS-PAGE and
reversed-phase HPLC before it was used for sequencing or
antibody production.

Figure 1 shows a broad band of the

purified tryptase on a SDS-PAGE gel.

The molecular weight was

determined to be 31, 000 ± 1, 000 {Figure 2).

The broad band is

due to different extents of glycosylation of the enzyme {see
below).

Reversed-phase HPLC of the enzyme {Figure 3) on a C4

hydrophobic column showed a single
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Figure 1.
SOS-PAGE Of Purified Tryptase.
Sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SOS-PAGE) was
performed using a Pharmacia PhastSystem. Purified rat skin
tryptase (0.7 µg) was separated on a 12.5% homogeneous gel
under denaturing and reducing conditions. The positions of the
molecular weight standards are indicated next to the sample.
The gel was developed with silver stain.
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Figure 2.
Molecular Weight Of Tryptase By SDS-PAGE.
Purified rat skin tryptase was separated on a 12.5%
homogeneous gel using a Pharmacia PhastSystem. Six molecular
weight standards on the indicated molecular weight are shown
in the open circles. The molecular weight of the standards at
a common logarithm scale are plotted against the corresponding
Rf values as defined in the text. An average Rf value for the
broad tryptase band is shown in the solid circle.
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Rf Values

0.8

1.0

33

Figure 3.
Reversed-Phase HPLC Of Purified Tryptase.
Purified rat skin tryptase was subjected to reversed-phase
HPLC chromatography using a C4 column. The separation
conditions are shown below.
Column: Aquapore Butyl {C4)
Mobile Phase: A: 0.1% TFA in ~o
B: 0.08% TFA in CH3CN
Gradient: 30-50% B, 20 minutes, linear
Flow Rate: 0.75 ml/min
Detection: UV, 206 nm
Sample: 4 µg tryptase
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peak under the specified conditions.
prior

to

the

sample

revealed

A control experiment run

an

identical

base

line.

subsequent N-terminal amino acid sequence analysis using the
Edman degradation method revealed a single sequence from the
purified tryptase.

2. Deglycosylation Of Tryptase

An enzymatic deglycosylation reaction was performed to
evaluate the extent and heterogeneity of glycosylation of
tryptase.

N-Glycanase

asparagine

amidase}

(Peptide-N4-(N-acetyl-P-glucosaminyl}
~

(Plumer

al.

1984}

catalyzes

the

hydrolysis of Asn-linked oligosaccharide at the P-aspartylglycosylamine
asparagine

bond

between

residue.

The

the

innermost

N-Glycanase

GlcNAc

releases

and

all

the

common

classes of Asn-linked oligosaccharide such as high-mannose,
complex

and

hybrid

oligosaccharide

including

sialylated,

phosphorylated, or sulfated sugar chains (Maley et al. 1989}.
Figure 4 shows that N-Glycanase modified the properties of
tryptase as observed by SDS-PAGE.

Lane 1 is the tryptase

treated with 1.65 units of N-Glycanase under the conditions
described

in Methods.

Lane

2

is

the untreated

tryptase.

Molecular weight standards are indicated in the figure.
untreated tryptase appeared as a broad band on the gel.

The
This

type of appearance is not uncommon for glycosylated proteins.
The presence of N-Glycanase reduced the broad band to a sharp
single band suggesting that
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Figure 4. SOS- PAGE Of N-Glycanase Treated Tryptase.
Sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SOS-PAGE)
was performed on a Pharmacia PhastSystem. N-Glycanase-treated
and untreated tryptase samples were separated in a 12. 5%
homogeneous PhastGel under denaturing and reducing conditions.
The positions of the molecular weight standards are indicated
next to the samples. The gel was developed in silver stain.
Lane 1 is the treated tryptase ( O. 4 µg) . Lane 2 is the
untreated tryptase (0.4 µg).
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Figure 5. Molecular Weight Change Following Deglycosylation.
Tryptase was enzymatically deglycosylated by incubation with
N-Glycanase and subjected to SDS-PAGE as shown in Figure 4.
The molecular weight standards are shown in the open circles.
The molecular weights of the standards on a common logarithm
scale are plotted against the corresponding Rf values as
defined in the text. Native tryptase and N-Glycanase treated
tryptase samples are shown in the solid circles. The
deglycosylated tryptase shows an apparent reduction of its
molecular weight by about 4,000 daltons.

39

O

Bovine Albumin 66,000

Ovalbumin 45,000

Pepsin 34, 700
Native Tryptase
Deglycosylated Tryptase
Trypsinogen 24,000

O

p-Lactoglobulin 18,400

Lysozyme 14,300
0.4

0.6

Rf Values

0.8

1.0

40

tryptase is glycosylated through asparagine linkages.

The

fact that tryptase was purified with a concanavalin A-agarose
column is consistant with this observation.

N-Glycanase in a

control, which contained 1.65 units of N-Glycanase and all of
the

other

detected

reaction

under

the

molecular weight of

components
above

except

experimental

tryptase was

tryptase,

was

not

conditions.

The

reduced by about

4, 000

daltons by N-Glycanase (Figure 5) .

3. Alkylation And Peptide Purification
Before fragmentation of tryptase, cystine residues of the
enzyme were converted to stable S-carboxymethylcysteine using
<3H)iodoacetic acid as described in Methods.

Residual salts

were removed from the alkylated protein through a Sephadex G25-80 column.

The column was calibrated with bovine serum

albumin (BSA) in NH4HC03 buffer.

Two separate BSA samples, 5

mg and 1 mg, were applied to the column.

In both cases, the

protein peaks fell into the same fraction numbers.

Consistent

result of the same calibration was obtained in another column
equilibrated with formic acid.

Calibration was performed

every time prior to desalting the alkylated protein.

The

protein was very well separated from the salts in the columns
under the conditions used.

The major salt peak did not come

out until after 16 ml of the solvents passed through the
column as indicated by precipitation of the salt.

Fractions

were counted in a P-counter to confirm the presence of the
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alkylated protein.
in Figure 6.

A typical alkylation result is presented

The calibration curve indicated that BSA came

out at fraction number 8 and 9.

Results of radioactivity

measurement precisely located the highest DPM values of the
alkylated and radiolabeled tryptase in the same fraction
numbers.
After alkylation, the protein was subjected to enzymatic
fragmentation. The cleavage of tryptase by enzymatic methods
results in a mixture of peptide fragments which must be
separated and purified before determination of their amino
acid sequence.

Analytical polyacrylamide gel electrophoresis

was performed in 12% gel containing 8 M urea.

Based on the

results, a fractionation method was selected for separation of
the peptides.

Three surface chemistries (butyl-, octyl-, and

octadecyl-} were used in an attempt to separate the peptides
according

to

their

different

hydrophobicities.

After

sufficient pilot testing, larger amount of the samples was
separated using a selected column and specific condition which
provided the best resolution.
Peptides from the tryptic digest were separated on a C18
column

(OD102,

Rainin} .

Figure 7 shows results of this

separation. All identifiable peaks were collected in separate
plastic tubes.

The shoulder of a peak was collected in a

separate tube to minimize any possible
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Figure 6. Desalting Of Alkylated Tryptase On A Sephadex G-2580 Column.
A G-25-80 Sephadex column was equilibrated in 9%
formic acid. A typical calibration curve for 1 mg BSA is shown
in the open circles. The absorbance values of BSA at 280 nm
are plotted against the fraction numbers. Elution of alkylated
tryptase is detected by the radioactivity in the fractions.
The fraction numbers are plotted against the DPM values shown
in the solid circles.
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Figure 7.
Tryptic Digest Of Tryptase.
Rat skin tryptase
fragments from a tryptic digest were separated by reversedphase HPLC using a C18 column on a Varian Model 5500 system.
All identifiable peaks were collected in separate plastic
tube. Peak number 19, 24, 31, and 37 were sequenced. The
conditions of the separation were as the follows.
Column: OD102 (Cl8)
Mobile Phase: A: 0.1% TFA in ~o
B: 0.08% TFA in C~CN
Gradient: 0-60% B, 60 minutes, linear
Flow Rate: 0.5 ml/min
Detection: UV, 206 nm
Samples: 20 µg tryptic peptides
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overlap of the peaks.

Peaks number 19, 24, 31, and 37 were

successfully sequenced without further purification.
The strategy for separation of the Lysylendopeptidase-C
(Lys-C} digest was different.

The digest was first subjected

to gel permeation chromatography (Figure 8)

to give three

peaks containing peptides of different sizes.

Peak 1 was then

subjected to reversed-phase HPLC using a C4 column (Figure 9}.
only one peak was observed which was subjected to amino acid
sequence determination.

4. Peptide Sequences
The

sequence

of

a

total

of

119

determined from 6 peptides (Figure 10).

amino

acids

were

Direct sequencing of

the purified tryptase produced a sequence of 37 amino acids
for the amino-terminus (N-T) indicating that the N-terminus is
not blocked.

The unambiguous sequence indicated that the

tryptase was purified to homogeneity.

A blank cycle appeared

at position 21, which was followed by aspartate and threonine.
The

site

for

an

N-glycosidic

linkage

has

the

general

structure: Asn-(X}-Ser or Thr, where X can be a variety of
amino acid residues.

Asn provides the attachment point for a

glycosyl chain which often contains terminal sialic acid
residues, galactose, mannose, and N-acetylglucosamine.

The

hydrophilic glycosyl groups in the glycosylated Asn residue
often

prevent

extraction

of

the

derivative during Edman sequencing.

Asn

anilinothiazolinone
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Figure
8.
Gel
Permeation
Chromatography.
The
Lysylendopeptidase-C (Lys-C) digest was separated by HPLC
using a gel permeation column. Three broad peaks are
identified. The separation conditions are shown below.
Column: Bio-Sil TSK-125, 60 cm L x 7.5 mm ID
Mobile Phase: 6 M quanidine HCl
10 mM potassium phosphate, pH 6
Flow Rate: 0.5 ml/min
Detection: UV, 226 nm
Samples: Lys-C digest
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Figure 9.
Separation By C4 Reversed-Phase Column.
Peak
number 1 from the gel penneation chromatography was subjected
to reversed-phase HPLC using a C4 column. A single peak was
identified. The separation conditions are shown below.
Column: BU300 {C4)
Mobile Phase: A: o .1% TFA in ~o
B: 0 .08% TFA in CH3CN
Gradient: 25-50% B, 25 minutes, linear
Flow Rate: 0.5 ml/min
Detection: UV, 206
Sample: peak number 1 of the Lys-C digest from gel
permeation chromatography
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The glycosylated residue is not normally identifiable through
a

regular

sequencing

procedure.

The

above

observation

together with the fact that the tryptase was purified from
concanavalin

A

column

and

deglycosylated

by

N-Glycanase

strongly suggest that the blank cycle could be an asparagine
residue in the putative glycosylation site.
The Lys-c peptide was sequenced through 23 amino acids.
A blank cycle was also present in this peptide at the sixth
position.
suggests

The presence of Ile and Thr after this
the

presence

of

another

glycosylation

cycle

site

in

tryptase.
A total of 59 amino acid residues were determined from
peptides Try-19, Try-24, Try-31, and Try-37 from the tryptic
digest.

Peptide Try-24 has an unidentified residue.
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Figure 10.
Peptide Sequences.
Purified peptides from rat
skin tryptase were sequenced by the Edman procedure using an
ABI 477A automated sequencer with on-line PTH analyzer 120 A.
Sequences of six peptides are presented in the figure. Nterminal: amino terminal sequence obtained by sequencing
purified
tryptase
directly;
Lys-C:
the
peptide
of
Lysylendopeptidase-C digest after C4 reversed-phase column
purification; Try-19, Try-24, Try-31, and Try-37: peptides of
the tryptic digest from peak number 19, 24, 31, and 37 after
C18 reversed-phase column chromatography; X: blank cycle
representing potential glycosylated Asn residue in the
sequence; Z: undetermined amino acid residue.
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PEPTIDES SEQUENCED

1. N-Terminal

Ile-V al-Gly-Gly-Gln-Glu-Ala-Ser-Gly-Asn-Lys-Trp-Pro-Trp-Gln-ValSer-Leu-Arg-Val-X-Asp-Thr-Tyr-Trp-Met-His-Phe-Cys-Gly-Gly-SerLeu-Ile-Asn-Pro-Glu
2. Lys-C
Leu-Thr-Asn-Pro-Val-X-Ile-Thr-Ser-Asn-Val-His-Thr-Val-Ser-Leu-Propro-Ala-Ser-Glu-Thr-Phe
3. Try-19
Gly-Leu-Asn-Thr-Gly-Asp-Asn-Val-His-Ile-Val-Arg
4. Try-24
Val-Asp-Met-Leu-Cys-Ala-Gly-Asn-Glu-Gly-His-Asp-Ser-Cys-Z-GlyAsp-Ser-Gly-Gly-Pro

5. Try-31
V al-Thr-Tyr-Tyr-Leu-Asp
6. Try-37
V al-Glu-Asp-Thr-Trp-Leu-Gln-Ala-Gly-Val-Val-Ser-Trp-Gly-Glu-GlyCys-Ala-Gln-Pro-Asn

CHAPTER V
DISCUSSION

partial Amino Acid Sequence Of Rat Skin Tryptase.
The sequence of 119 amino acids determined for rat skin
tryptase account for about 45% of the total primary sequence
of the enzyme.

Among all tryptases, rat skin tryptase is the

first to be sequenced to this extent by the Edman procedure.
As mentioned in the

literature review section, amino acid

sequences of other tryptases have all been derived from cDNA
sequences.

Although precise assignment of any of the amino

acid sequences to a functionally active tryptase remains to be
clarified, the primary sequences still provide a wealth of
information

for

analysis

properties of tryptases.

of

the

potential

structural

The six peptides from rat skin

tryptase were aligned to the corresponding regions of other
tryptase sequences as shown in Figure 11 according to the
alignment data generated by GCG (Devereux et al. 1984) and
others (Johnson & Barton 1992) .
used.

Tryptase numbering system is

The homology between each peptide and its corresponding

portion in other tryptase sequences is summarized in Table 2.
References

to

the

tertiary

structures

is made

based on

computer models of serine proteases (Greer 1990) and tryptase
(Johnson & Barton 1992).
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Figure 11. Tryptase Sequence Alignment.
Peptide sequence of
rat skin tryptase are compared with the amino acid sequences
of bovine trypsin and other tryptases. Sequence alignment is
constructed based on the earlier presentation (Chen et al. 90)
and a recent report (Johnson & Barton 92). Amino acid
positions of tryptase are indicated beneath the first digit of
each number. BT, bovine trypsin; HLTa, human lung tryptase a
(Miller et al. 89} ; HLTP, human lung tryptase P (Miller et al.
90), which is identical to human skin tryptase 2 (Vanderslice
et al. 90); HSTl, human skin tryptase 1; HST3, human skin
tryptase 3; DMT, dog mastocytoma tryptase (Vanderslice et al.
89); MMCTl, mouse mast cell tryptase 1 (Chu 90); MMCT2, mouse
mast cell tryptase 2, which is identical to mouse mast cell
protease 6 (Reynolds et al. 91}; •, identifies the catalytic
site histidine, aspartate, and serine; +, points to the
substrate binding site aspartate; and *, highlights the
putative glycosylation sites in small letters.
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BT

HLTa
HLT/J
HSTl
HST3
DMT
MMCTl
MMCT2
RST
BT

HLTa
HLT/J
HSTl
HST3
DMT
MMCTl
MMCT2
RST
BT

HLTa
HLT/J
HSTl
HST3
DMT
MMCTl
MMCT2
RST

1
11
*
31
41 •
51
61
71
81
IVGGYTCGANTVPYQVSLN SGY HFCGGSLINSQWVVSAAHCYKSGIQVRLGEDNINVVEGN
EQFISASKSIVHPSYN
IVGGQEAPRSKWPWQVSLRVRDRYWMHFCGGSLIHPQWVLTAAHCLGPDVKDLATLRVN SGTHLYYQDQLLPVSRIMVHPQFY
IVGGQEAPRSKWPWQVSLRVHGPYWMHFCGGSLIHPQWVLTAAHCVGPDVKDLAALRVQLREQHLYYQDQLLPVSRIIVHPQFY
IVGGQEAPRSKWPWQVSLRVHGPYWMHFCGGSLIHPQWVLTAAHCVGPDVKDLAALRVQLREQHLYYQDQLLPVSRIIVHPQFY
IVGGQEAPRSKWPWQVSLRVRDRYWMHFCGGSLIHPQWVLTAAHCVGPDVKDLAALRVQLREQHLYYQDQLLPVSRIIVHPQFY
IVGGREAPGSKWPWQVSLRLKGQYWRHICGGSLIHPQWVLTAAHCVGPNVVCPEEIRWQLREQHLYYQDHLLPVNRIVMHPNYY
IVGGHEASESKWPWQVSLRFKLNYWIHFCGGSLIHPQWVLTAAHCVGPHIKSPQLFRVQLREQYLYYGDQLLSLNRIVVHPHYY
IVGGQEAHGNKWPWQVSLRAndtYWMHFCGGSLIHPQWVLTAAHCVGPDVADPNKVRVQLRKQYLYYHDHLMTVSQIITHPDFY
IVGGQEASGNKWPWQVSLRVxdtYWMHFCGGSLINPQ
•
*
111
121
131
141
151
161
SNTLNNDIMLIKLKSAASLNSRVASISLPTSCA SAGTQCLISGWGNTKSS GTSYPDVLKCLDAPILSDSSCKSAYP
IIQTGADIALLELEEPVnisSRVHTVMLPPASETFPPGMPCWVTGWGDVDNDEPLPPPFPLKQVKVPIMENHICDAKYHLGAYT
TAQIGADIALLELEEPVKVSSHVHTVTLPPASETFPPGMPCWVTGWGDVDNDERLPPPFPLKQVKVPIMENHICDAKYHLGAYT
TAQIGADIALLELEEPVnvsSHVHTVTLPPASETFPPGMPCWVTGWGDVDNDERLPPPFPLKQVKVPIMENHICDAKYHLGAYT
TAQIGADIALLELEEPVnvsSHVHTVTLPPASETFPPGMPCWVTGWGDVDNDERLPPPFPLKQVKVPIMENHICDAKYHLGAYT
TPENGADIALLELEDPVnvsAHVQPVTLPPALQTFPTGTPCWVTGWGDVHSGTPLPPPFPLKQVKVPIVENSMCDVQYHLGLST
TAEGGADVALLELEGPVnvsTHIHPISLPPASETFPPGTSCWVTGWGDIDNDEPLPPPYPLKQVKVPIVENSLCDRKYHTGLYT
IVQDGADIALLKLTNPVnisDYVHPVPLPPASETFPSGTLCWVTGWGNIDNGVNLPPPFPLKEVQVPIIENHLCDLKYHKGLIT
STNPVxitSNVHTVSLPPASETF
GLNT
171
181
•
191•
*
211
221
231
241
GQ
ITSNMFCAGYLEGGKDSCQGDSGGPVVC SGK LQ GIVSWGSGCAQKNKPGVYTKVCNYVSWIKQTIASN
GDDVRIIRDDMLCAG NSQRDSCKGDSGGPLVCKVngtWLQAGVVSWDEGCAQPNRPGIYTRVTYYLDWIHHYVPKKP
GDDVRIVRDDMLCAG NTRRDSCQGDSGGPLVCKVngtWLQAGVVSWGEGCAQPNRPGIYTRVTYYLDWIHHYVPKKP
GDDVRIVRDDMLCAG NTRRDSCQGDSGGPLVCKVngtWLQAGVVSWGEGCAQPNRPGIYTRVTYYLDWIHHYVPKKP
GDDVRIVRDDMLCAG NTRRDSCQGDSGGPLVCKVngtWLQAGVVSWGEGCAQPNRPGIYTRVTYYLDWIHHYVPKKP
GDGVRIVREDMLCAG NSKSDSCQGDSGGPLVCRVRGVWLQAGVVSWGEGCAQPNRPGIYTRVAYYLDWIHQYVPKEP
GDDFPIVHDGMLCAG NTRRDSCQGDSGGPLVCKVKGTWLQAGVVSWGEGCAQPNKPGIYTRVTYYLDWIHRYVPEHS
GDNVHIVRDDMLCAG NEGHDSCQGDSGGPLVCKVEDTWLQAGVVSWGEGCAQPNRPGIYTRVTYYLDWIHHYVPKDF
GDNVHIVRVDMLCAG NEGHDSCZGDSGGP
VEDTWLQAGVVSWGEGCAQPN
VTYYLD
U1
O'I

.""'II

BT
HLTa
HLTfl
HS Tl
HST3
DMT
MMCTl
MMCT2

N-Ter
(37)

Lys-C
(23)

Try-19
(12)

Try-24
(21)

Try-31
(6)

Try-37
(21)

Overall
(119)

68
86
84
84
86
73
76
92

26
78
70
74
74
52
61
78

0
58
67
67
67
75
58
92

64
80
80
80
80
80
75
95

33
100
100
100
100
83
100
100

67
90
90
90
90
86
90
100

43
82
81
82
82
75
77
93

Table 2. Peptide Sequence Homology.
Peptide sequences from rat skin tryptase were
compared with the corresponding portion of the amino acid sequence of other tryptases.
The table gives the percentage of the identity of each peptide from rat skin tryptase to
the corresponding regions in other tryptases.
The overall identity is also indicated.
The number of amino acids in each peptide is indicated in a parentheses.
BT, bovine
trypsin; HLTa, human lung tryptase a (Miller et al. 89); HLTfl, human lung tryptase fl
(Miller ~ .s!l. 90), which is identical to human skin tryptase 2 (Vanderslice §t. .s!l. 90);
HSTl, human skin tryptase 1; HST3, human skin tryptase 3; DMT, dog mastocytoma tryptase
(Vanderslice~ al. 89); MMCTl, mouse mast cell tryptase 1 (Chu 90); MMCT2, mouse mast
cell tryptase 2, which is identical to mouse mast cell protease 6 (Reynolds et al. 91);
N-Ter, N-terminal amino acid sequence from rat skin tryptase; Lys-C, the peptide from
lysylendopeptidase-C digest; Try-19, Try-24, Try-31, and Try-37, the peptides of peak
number 19, 24, 31, and 37 respectively from the tryptic digest.
U1

-..J
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The structural differences between tryptases and trypsin
has been described in a recent paper (Johnson & Barton 1992).
The homology between tryptases and trypsin is about 49% with
2 0-21 additional amino acids for tryptases.
peptides

(Chen~

to trypsin.

on

al. 1990) show a low overall identity (43%)

Some regions are highly conserved among trypsin

and tryptases.
(based

The catalytic site H44, D91, and S194 residues

tryptase

numbering

tryptases and trypsin.
which

Rat skin tryptase

is

system)

are

present

in

all

So is the substrate binding D188,

characteristic

of

trypsin-like

chymotrypsin-like serine proteases.

rather

than

However, tryptase does

show some marked differences from trypsin.

The most distinct

feature of tryptases is the two insertions on either side of
the active site cleft compared with trypsin.

There are four

more amino acid residues in tryptase than in trypsin between
residues 20 and 26 (Figure 11) .

There is also a 9 amino acid

insertion located between 164 and 174.

Both of the insertion

sites are

involved in inhibitor binding region of serine

protease.

These two insertions may contribute to the higher

substrate selectivity of tryptase as well as to the resistance
of

tryptase

feature
residues

of

to many
tryptases

and

proline

trypsin
is

inhibitors.

the

patches.

tryptophan residues than does

extra

Another unique

number

Tryptase
trypsin.

of
has

tryptophan
five

more

Three dimensional

modeling of tryptase (Johnson & Barton 1992) based on trypsin
structure reveals that four of the five tryptophan residues
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not found in trypsin, W12, 14, 126, and 206, form a cluster on
the opposite side of the active site.

There is another

hydrophobic stretch between L139 and L145 which includes the
proline patches along one edge of the tryptase model (Johnson
&

Barton 1992) .

The sequences obtained from the rat skin

tryptase peptides account for four of the tryptophan residues
unique to tryptase.

Three of them, W12, 14, and 25, are

located in the N-terminal peptide.
located in the Try-37 peptide.

The other one, W206, is
Tryptophan,

leucine,

and

proline residues in tryptase seem to have arisen from mutation
rather than insertion. Tryptase is a tetramer. The hydrophobic
regions may play a

role

in the

interaction between the

subunits.
Tryptase is a mediator of mast cell granule and released
together with heparin from mast cell during degranulation
(Pearce 1989).
heparin

Human lung tryptase activity is stabilized by

(Schwartz

& Bradford

that

1986).

tryptase

The

somehow

observations

mentioned

suggest

interacts

with

heparin.

Binding to heparin requires that tryptase have

sufficient surface positive charges (Blankenship et al. 1990).
Amino acid sequences show that tryptase has 6 more lysine and
arginine, and 7-10 more histidine residues than trypsin does.
These basic residues are found on the surface of the molecule
indicating that they may play a role in heparin binding.
Human tryptase has been shown to bind to heparin at neutral pH
as well as at acidic pH.

The pKa for histidine is 6, which

r
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suggest that histidine may not be an important factor for
heparin binding at neutral pH.
more important

role

However, histidine may play a

in heparin binding inside mast

cell

granules which has a pH value of 5.6 {DeYong et al. 1987).
since the pI values for lysine and arginine are 9.7 and 10.8
respectively,

they are believed to have a major role in

extracellular tryptase binding to heparin at neutral pH.

In

spite of the potential role of the basic residues, charges
alone should not be over emphasized.

Trypsin has a net charge

of +5 in comparison to -4 to -10 for tryptase due to more
total acidic residues. Further evidence is needed to identify
the heparin binding sites.

Rat skin tryptase, which has an

overall 92% homology to MMCT-2, does not show evidence of
heparin binding in vitro {Braganza & Simmons 1991) •
Another difference of tryptase from trypsin is that all
tryptases identified are glycosylated, which is not the case
in trypsin.
found

in

A number of putative glycosylation sites are
all

tryptases

in

Figure

11.

Enzymatic

deglycosylation of the purified tryptases showed the molecular
weight of tryptase shifted to a smaller size after incubation
with deglycosylation enzymes as shown in the results above and
else where {Cromlish et al. 1987, Braganza & Simmons 1991).
Like other tryptases, rat skin tryptase peptides significantly
differ from trypsin with only from O to 68% homology between
the corresponding regions {Table 2).
While the differences between tryptase and trypsin is
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the

remarkable,
significant.

distinction

among

tryptases

is

also

Rat skin tryptase peptide sequences and other

tryptase sequences have revealed a great extent of homology as
well

as

differences.

The

conunon and unique

functional

properties of tryptases may be the result of the structural
similarities
tryptases,

and

rat

differences

among

Like

them.

skin tryptase peptides

have

other

revealed the

conserved residues such as the catalytic site residue S194,
substrate binding site

residue 0188,

and

the

tryptophan

residues specific to tryptase but not to trypsin, W12, W14,
W25, and W206.

Residues between 0188 and C200 located next to

the active site of serine protease are highly conserved among
tryptases.

This region show 100% amino acid identity among

tryptases except HLT-a which has a 92% identity.

The stretch

from W206 to N222 starts from one side opposite to the active
site, passes through the interior of the molecule, and reaches
the region on the other side near the substrate binding site
according to the computer models

(Johnson

&

Barton 1992) .

Yet, this long stretch reserves about 100% amino acid identity
among all of the tryptases including rat skin tryptase.

The

highly homologous

the

regions

sampled above may

ref le ct

underlying structural identity which determines the functional
similarities among tryptases.
The unique functional properties of tryptases may be
related to their structural variations.

Within the two

insertions, residues 20-26 and 164-174, high degree of amino

r
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acid variation among the tryptases is apparent.

In the

insertion between residues 20 and 26 on one side of the active
site clef, for instance, the amino acid at position 23 among
the tryptases varies significantly.

HST-1 and HLT-P have a

hydrophobic proline residue at the position.

HST-3 and HLT-a

have basic amino acid residues, lysine and arginine instead.
While MMCT-1 and DMT have asparagine or glutamine with an
amide

group,

both RST and MMCT-2

threonine with a hydroxyl group.

have a

more aliphatic

Tolerance to this type of

mutational change would mean that the position either has
little biological

significance

to

the

enzyme or defines

certain functional specificity for tryptase.

Location of the

position in the inhibitor binding region tends to support the
latter.
174)

The amino acids in the other insertion region (164-

also

revealed some variations

different species.

among

tryptases

from

For example, all human tryptases have

alanine at position 166 while mouse, dog, and rat tryptases
have

leucine

instead.

While

all

the

human and

the

dog

tryptases have an arginine at position 173, tryptases in mouse
and rat have either praline or histidine.
well

documented

substrate binding

site

replaced by a valine in elastase (Shotton

Glycine 215 is a
residue which is

&

Watson 1970).

The

glycine residue in HLTa is replaced by an aspartate.
Another obvious difference among the tryptases is the
location and number of the putative glycosylation sites.

All

human tryptases have a putative glycosylation site at position
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A highly
2 03 while rat, mouse, and dog tryptases do not.
conserved putative glycosylation site is located at position
1 02 in all tryptases except HLT-P.

Both of the two positions

are on the opposite side of the active site according to the
three dimensional models proposed for serine proteases (Greer
1990) and tryptases (Johnson

&

Barton 1992) . Another putative

glycosylation site which does not exist in other tryptases is
located at position 21 in MMTC-2 and RST.

This position

appears to be in a region near the substrate binding site.
The

functional

importance

of

the glycosylation sites

in

tryptases remain unclear.
The results have revealed some interesting structural
properties of tryptases.

The structural characteristics of

tryptase provide very encouraging and helpful information for
future exploration of the structure and function relationship
of the enzyme.

r

PART II

RAT MAST CELL HETEROGENEITY
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CHAPTER VI
INTRODUCTION

The pace of mast cell research has been exceptionally
rapid during the past several years because of the potential
biochemical and clinical importance.

The most recent advances

in mast cells are summarized in the review section.

Mast

cells are localized inunune cells which have been implicated in
the pathogenesis of many human disorders.
types

have

been

described

in

rodent

Different mast cell
and

human

tissues.

Understanding mast cell heterogeneity is very important for
identification of the precise role of each mast cell type in
different disease states.

In rats, mature mast cells are

grouped under two major subsets, the connective tissue mast
cells and mucosa! mast cells,
properties.

based on their dye-binding

Alcian blue identifies both the mucosa! mast cell

type which contains chondroitin sulfate proteoglycans, and the
connective tissue mast cell type, which contains heparin and
chondroitin

sulfate

proteoglycans.

Saf ranin

stains

proteoglycan and thereby selectively stains the connective
tissue mast cell type.

In general, mature cells that remain

blue after the alcian blue/safranin double stain would belong
to the mucosa! mast cell type; those which counterstain red
are

of

the

connective

tissue mast

cell

type.

However,

immature connective tissue mast cells stain with alcian blue,
65
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but poorly,
binding

if at all, with safranin.

properties

of

mast

Therefore,

cells

have

the dye-

limitations

discriminating markers of the two mast cell types.

as

Recently,

mast cell granular enzymes have been used successfully as
markers

in

the

identification

of

mast

cell

subsets.

Monospecif ic and monoclonal antibodies against rat mast cell
chymase

I

and

chymase

II

were

used

to

distinguish

the

connective tissue mast cell from the mucosal mast cell type
respectively.
tissue

mast

submucosa,

Anti-chymase I antibody identified connective
cell

and

in

lung

skin,

tongue,

pleural

intestinal

membrane.

serosa and

Anti-chymase

II

antibody identified mucosal mast cells as the predominant type
in mucosa of small intestine and stomach.

Chymase II positive

mast cells also were detected in other tissue locations such
as around bronchi, thymus, liver, and submucosa of stomach.
In humans, mast cells have also been classified based on
their

neutral

tryptase;

protease

content.

One

the other contains tryptase,

type

contains

chymase,

only

mast cell

carboxypeptidase and a cathepsin G-like protease.

Based on

tissue distribution, the type with only tryptase corresponds
more closely to the rat mucosal mast cell type while the other
type corresponds more closely to the connective tissue mast
cell type in rat.
In the current study, rat tryptase is shown to be located
only in a subpopulation of the safranin-positive, chymase Ipositive mast

cells

of

the

connective

tissue

type.

The
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obvious distinction of tryptase distribution in human mast
cell population and rat mast cell population may reflect an
interesting evolutionary

aspect of the two species.

,
CHAPTER VII
LITERATURE REVIEW

It's been more than 100 years since mast cells were first
described (Ehrlich 1878, Schwartz & Huff 1991}.

This chapter

is designed to briefly summarize the most recent advances in
our knowledge about mast cells and to elicit an appreciation
of the significance of mast cell research.

1. Biological And Pathological Roles
Thanks to the advance in cell biology, biochemistry, and
molecular biology techniques, mast cell research has gained
momentum in the past few years.
publications,
reported.

it

is

Due to the large number of

impossible to cover all

the details

In this section, the biological and pathological

roles of mast cells are reviewed to help understand mast cells
and their important roles in health and diseases.

Mast cells

are granulocytic immune cells that are frequently found at the
interface

of

Degranulation

the
occurs

internal
when

and

mast

external
cells

are

environments.
stimulated

antigens via IgE molecules on the cell surface (Segal

.§.t.

by
al.

1977} or other endogenous and exogenous secretogogue such as
hormones, neurofactors, cytokines, and physical stimuli such
as heat, cold, or trauma (Bernstein & Lawrence 1990, Galli
1990} .

The biologically active mediators released from the
68
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granules interact with the local environment in a unique way
and facilitate the initiation of some normal or pathological
events.
The role of mast cells in

Mast cells in the airway.

bronchial

asthma

has

been well

Schwartz & Huff 1991).

in

(Maron

1991,

Brochial asthma, a manifestation of

immediate hypersensitivity,
increase

established

is a

responsiveness

of

disease characterized by
bronchial

smooth

muscle,

cellular infiltration, and glandular tissue secretion.

Mast

cells are present in abundance in bronchial and alveolar (Fox
et al.

1981,

Release

of

Schulman

gl.

_g_t.

mediators

from

the

1982,

Irani

effector

et

al.

cells

in

1986).
these

locations can directly affect the activity of the respiratory
tract. When challenged with endobronchial allergen (Wenzel et
al.

1988)

or oral aspirin

(Basso et al.

1989),

mast cell

activation occured as indicated by elevated plasma levels of
In cases where airway obstruction

tryptase and histamine.
occurs,
(Broide

mast cell activation and degranulation also occur
~

rhinitis,

al.

1991,

Jarjour et g],_.

1991).

In allergic

the immediate response correlates with mast cell

degranulation

(Sedgwick et al. 1991).

Following this mast

cell mediated immediate response, eosinophils are attracted to
the airway and cause airway injury during
allergic

reaction.

Mast

cells

are

the late-phase

also

involved

in

experimentally induced nasal allergic response (Walden et al.
1988).

It

was

reported

that

mast

cells

participate

in
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pulmonary fibrosis when rats are challenged with bleomycin or
asbestos (Goto et al. 1984, Wagner et al. 1984).

When mast

cells were co-cultured with fibroblast and mesothelial cells,
two predominant and yet morphologically distinct neighboring
cell types, and mast cell degranulation was induced by 48/80,
subsequent

induction

of

mitogenesis

occurred

in

both

fibroblasts and mesothelial cells (Druvefors & Norrby 1988).
The observation supports the role of mast cells in fibrosis.
However, whether the mast cells cause pulmonary fibrosis or
result from the fibrosis remains unclear.
that

pulmonary

fibrosis

could be

induced

The observation
in mast

cell-

deficient mice suggested the possibility that the increase of
mast cell number might be the result of pulmonary fibrosis
(Mori et al. 1991).
Mast cells in gastric system. The participation of mast

cells in gastrointestinal infections has been documented. Mast
cells are found in large number in intestinal mucosa (Enerback
1966, Fox

gt.

al. 1985).

Parasitic infection dramatically

increases mast cell population in the mucosal area in rodents
(Mayrhofer 1979a, 1979b, Mayrhofer & Bazin 1981, Stevens et
al. 1986).

After roundworm infection, rat mucosal mast cells

degranulate and result in elevated levels of secreted chymase
II (Woodbury et al. 19 84) , a serine protease which may enhance
vascular permeability, suggesting that mast cell activity may
play an important role in resisting parasite infection.

Mast

cells have been found to be responsible for the acute gastric
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damage and restraint stress-induced gastric ulceration (Guth

& Kozbur 69, Andre et al. 85, Galli et al. 85).

Compound

4 9/80 causes mast cell degranulation leading to severe gastric
lesions (Franco

~

gl. 1959, Cho _g.t_ al.

1980, Takeuchi et al. 1986).

1979, Ogle gt. al.

Ethanol is known to cause mast

cell-dependent augmentation of acute gastric mucosal damage
(Wallace et gl. 1982, Galli et al. 1985).

Sodium cromoglycate

and

inhibit

FPL-52694

are

agents

known

to

mast

cell

degranulation and are called mast cell stabilizers (Takeuchi
et al. 84,

al. 1987).

Goossens~

These agents have been

shown to inhibit gastric damage resulting from changes in acid
secretion and gastric motility induced by compound 48/80,
ethanol, restraint stress and other compounds which cause mast
cell degranulation (Ogle & Lau 1980, Canfield & CUrwain 1983,
Takeuchi et al. 1984, Takeuchi
1987,

Wallace et al.

1988,

~

al. 1986, Goossens et al.

Beck et al.

1989).

In rats

pretreated with the two mast cell stabilizers, the number of
mast cells were significantly reduced in the ethanol treated
rats.

Correspondingly,

both agents significantly reduced

ethanol- induced damage in a dose dependent manner (Beck et al.
1989).
Mast cells and tumors.

There is an increasing amount of

evidence for mast cell interaction with tumor cells (Hartveit
1981, Hartveit et al. 1984, Parwaresch et al. 1985, Ionov
1989, Flynn et al 1991).

Mast cells have been found at tumor

sites (Dabbous 1980, Van den Hooff et gl. 1983, Woolley 1984,

72
Roche 19 85) .

Degranulation of mast cells at these sites

suggests that mast cell-tumor cell interactions might enhance
invasive growth of human and animal tumors (Csaba

§..t.

al. 1961,

Hartveit & Sandstad 1982, Farnoush & Mckensie 1983, Norrby &
Enstrom 1984) .

Previous studies had shown that extensive

extracellular matrix degradation was associated with tumor
invasion and metastasis (Yamanishi et al. 1972, Hashimoto et
al.

1973,

Liotta

~

gl.

1980).

In terms of release of

collagenolytic activity, tumor-derived fibroblast-like cells
appeared to be more responsive to mast cell products than did
normal fibroblasts

(Dabbous et al.

1986) .

The mast cell

factors responsible for stimulating collagenolytic activity
were apparently not histamine or heparin.

In more recent

studies (Gruber et gl. 1988, 1989), tryptase was shown to have
a potential role in matrix degradation via activation of
prostromelysin
extracellular
collagenase.

to

stromelysin

matrix

which

components

and

in

turn

activates

degrades
latent

Studies using mast cell-stabilizing compounds

provided support for mast cell involvement in tumor metastasis
(Dabbous et al. 1991).

Rat pretreated with FPL 55618 which

prevents mast cell degranulation, caused a 70% inhibition of
tumor growth at the primary site.

After 23 days without

treatment, tumor growth of the rats accelerated and reached a
similar tumor size to that of control animals.

Numerous mast

cells were detected around the tumor periphery and often
showed signs of degranulation.

In contrast to the untreated

r
:
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animals, FPL 55618 treated animals showed numerous intact mast
cells

within

the

In

tumor mass.

contrast

to

in vivo

experiments, FPL 55618 had no direct effect on the rate of rat

mammary adenocarcinoma proliferation in vitro.

Soluble mast

cell product, on the other hand, significantly increased the
rate

of

tumor

cell

These

proliferation.

observations

demonstrated the potential importance of mast cell and tumor
cell interaction in the growth and invasive properties of
tumor cells in vivo.

In IgE-dependent mast cell activation,

the inunediate release of preformed mast cell mediators is
followed

by

synthesis

and

sustained

release

of

large

quantities of newly formed tumor necrosis factor alpha (Gordon
& Galli

1991) .

Ma.st

cells

have

been

implicated

in

angiogenesis in tumor sites (Messler et al. 1976, Fraser &
Simpson 1983, Starkey et al 1988, Crowle

&

Starkey 1989) .

Tumor necrosis factor is mitogenic for fibroblasts (Dayer et
al.

1985,

Young et g!.

1987)

and capable of stimulating

angiogenesis in vivo (Kessler et al. 1976, Frater-Schroder et
al. 1987, Leibovish

~

al. 1987).

influence mast cell differentiation

Fibroblast can in turn
(Levi-Schaffer et al.

1986) and granule maturation (Davidson

~

al. 1983).

Ma.st

cell granules can actually be transferred into fibroblasts via
phagocytosis

(Nicolson 1984,

Norrby

&

Enstrom 1984)

and

transgranulation (Greenberg & Burnstock 1983), a process in
which mast cells establish a special cell contact with other
cell types and release its granule into the contact cell.

The
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specific role of mast cells in tumor growth and metastasis
remain an interesting area of investigation.

Mast cells and the nervous system. Interaction of mast
cells with the nervous system has been widely reported (Olsson
1968, Ibrahim 1974, Dropp 1976, Theoharides 1990, Johnson &
In the brain, greater than 98% of the mast

Krenger 1992).

cells are located in the thalamus (Goldsehmidt et al. 1984).
The connective tissue coverings of the central nervous system
are also rich in mast cells (Orr 1988, Ferrante et al. 1990,
Dimlich gt. al. 1991).

In the peripheral nervous system, mast

cells are located in the autonomic nerve endings in tissues
such as skin

(Heine

Forster 1975,

&

Alving et al.

1991),

thymus and spleen (Williams & Felten 81, Weihe et al. 1989,
Muller & Weihe 1991), intestine (Newson et al. 1983, Stead et
al.

1987, Stead et al.

1989), mesentery

(Skofitsch et al.

1985), and lung (Bienenstock et al. 1988, Alving et al. 1991).
Several

studies

have

suggested

that

mast

cells

and

nervous tissues may interact with each other bidirectionally
(Barrett 1991) .

There is evidence that the nervous system can

influence the growth, differentiation, and degranulation of
mast cells.
show

its

When co-cultured with mast cells, glial cells

ability

(Seeldrayer

~

to

support

mast

cell

.sU:,. 1989, Ryan & Huff 1990).

are known to secrete nerve growth factor
1987,

Houlgatte

development.

~

al.

1989}

growth

in

vitro

The glial cells
(Lindholm et al.

which can affect mast

cell

In cell culture, addition of nerve growth factor
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increases the number and size of mast cells (Aloe 1977, 1988).
When spleen cells pretreated with nerve growth factor were
injected

into

the

brains

of

developing

rats,

the

cells

differentiated into mast cells (Aloe & DeSinone 1989).

While

the ability of noradrenaline and acetylcholine to stimulate
mast cell degranulation is still controversial (Manunaioini et
al. 1975, Fantozzi gt. Sil. 1978, Kazimierczak et al. 1980, Alm

& Bloom 1981, Masini et al. 1985, Botana et al. 1987), many
neuropeptides

have

been

Somatostatin induces

shown

to

degranulation of

cells and human skin mast cells
1980,

P

mast

cells.

rat peritoneal mast

(Theoharides et al.

& Foreman

1985,

Renold

(Erjavec gt. Sil.

1981,

Fewtrell

Piotrowski

Substance

activate

et
et

al.

1978,
1987).

al.

1982,

Shibata et al. 1985, Ebertz et al. 1987), endorphins (Yawasaki
et al. 1982, Shanahan et al. 1984), neurotensin (Lazarus et
al. 1977, Sydbom 1982), opioid peptides (Casale et al. 1984),
vasoactive intestinal peptide

(Piotrouski

calcitonin gene-related peptide

&

Foreman 1985),

(Fremann 1987),

neurokinin

(Wallengren & Hakanson 1987) , prostaglandin D2 (Levi-Schaffer

& Shalit 1989), and neuropeptide Y (Arzubiaga et al. 1991) are
all

capable

of

causing

mast

cell

through the P-adrenergic receptors
1982,

Lowman~

degranulation,

perhaps

(Marquarett & Wasserman

al. 1988, Arbabian gt. al. 1989) and muscarinic

cholinergic receptor (Masini

~

al. 1983) on the surface of

mast cells.
Mast cells can also influence nervous tissue.

Histamine,
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a mast

cell mediator,

is

a

neurotransmitter

capable of

regulating synaptic transmission (Steinbusch & Muller 1984,
Villena et al. 1986, Weinreich & Undem 1987, Christian et al.
1989, Wada t t

1991) and inducing electrophysiological

gl.

changes in vitro (Green et al. 1988, Janiszewski et al. 1990).
rromunological regulation of synaptic transmission has been
observed in isolated guinea pig autonomic ganglia (Weinreich
~

al. 1987) and in patients with allergic disease (Casale

1983).

Mast

cells

hydroxytryptamine,

a

can

affect

the

neurotransmitter,

in

content
rodent

of

5-

sensory

ganglia (Kai & Keen 1985), and rat intestinal motor (Bueno tt
al. 1991).

Serotonin, vasoactive intestinal peptide, and

somatostatin-like molecules secreted by mast cells of brain
and other tissues may also modulate the neural activities in
the nervous system (CUtz et s.l. 1978, Goetzl tt al. 1985,
Lambracht-Hall tt al. 1990).
Besides serving as sources of neurotransmitters, mast
cells can also regulate local neuronal activities through
modification or processing of other neural peptides by mast
cell

neutral

proteases.

As

mentioned

earlier,

tryptase

selectively hydrolyzes potent bronchodilators such as VIP,
PHM, and CGRP but not the bronchoconstrictor SP.
Although

the

mechanism of

mast

interaction has not been resolved
Bienenstock et
been

gl.

uncovered

cell/nervous

system

(Marshall et s.l.

1989,

1991) , evidence for such interactions have

in

many

neural

disorders

such

as

CNS
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inflammatory demyelination {Mokhtarian

&

Griffin 1984, Griffin

& Mendoza 1986), systemic mastocytosis {Rogers et al. 1986,
Iriarte et al. 1988,

Schwartz~

{Isaacson 1976, Riccardi
1987,

Johnson~

nerve

disease

example,

&

gl. 1987), neurofibromatosis

Eichner 1986, Claman 1987, Riccardi

gl. 1989, Riccardi, 1989), and in peripheral

{Barnes

et

al.

1990,

Kiernan

1990).

For

increased mast cell degranulation was detected in

experimental allergic encephalomyelitis {EAE), a model of CNS
demyelination {Bo

~

gl. 1990, Krenger et al. 1991).

Mast

cell degranulation was also observed in experimental allergic
neuritis {Powell et al. 1983, Izumo et al. 1985, Seeldrayers
~

al.

1989).

The precise

role

of

mast

cell

in

these

disorders remain to be defined.
Involvement of

Mast cells in the cardiovascular system.

mast cells in the cardiovascular system has gained increasing
attention in the past several years. The role of mast cells in
atherogenesis {Kovanen 1991) and angiogenesis {Rakusan et al.
1990)

have

coronary

been

investigated.

atherosclerosis

accumulation

of

are

LDL-derived

The

molecular

characterized
cholesterol

by

in

the

events
the

in

local

coronary

intima, the innermost layer of the arterial wall {Smith 1974,
Richardson

~

al. 1989, Movanen 1990).

In the early stage,

macrophages in the intima absorb cholesterol from modified LDL
and become foam cells filled with cholesterol ester droplets
{Fogelman et al.
accumulate

in

1988, Hoff et al. 1990).

the

foam

cells

and

then

Cholesterol can
extend

from

its
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intracellular
cholesterol
develops
1987,

position

core

(Smith

to
1974,

form

a

soft

Guyton g.t. al.

into atherosclerotic lesions

Stehbens

1987) •

extracellular

However,

(McGill

studies

1990)

which

1968,

Stary

have

shown

that

macrophages do not endocytose LDL unless the LDL molecules are
first modified (Goldstein et al. 1979, Steinberg et al. 1989),
a process which may involve mast cells.
Mast cells have been detected in the arterial intima
(Pollak 1957, Pouchlev

~al.

1966, Kamio et al. 1979).

An

extensive autopsy study of human from birth to age 39 showed
that twice as many mast cells were present in the arterial
intima of both early and advanced atherosclerotic lesions
compared to non-disease intima (Stary 1990) .

The role of mast

cells in atherosclerosis has been proposed based on both in
vitro and in vivo experimental results.

After degranulation

of mast cells, heparin released from the granules binds to the
positively charged domains of apolipoprotein B and E on LDL
(Kokkonen & Kovanen 1987a, 1989, Kovanen & Kokkonen 1991).
Mast

cell

granular

carboxypeptidase A,
surface (Kokkonen

&

proteases,

mainly

chymase

and

degrade the apolipoproteins on the LDL
Kovanen 1985, Kokkonen et al. 1986).

This

results in modified LDL molecules binding to the mast cell
granule

remnant

which

are

ultimately

macrophages located nearby (Lindahl

gt. gl.

phagocytosed

1979, Baggiolini g.t.

al. 1982, Kokkonen & Kovanen 1987b, Lindstedt
Under

normal

circumstances,

by

prevention

of

~

al. 1992).
cholesterol
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accumulation in arterial intima can be facilitated by high
density lipoprotein (HDL) (Kovanen 1990). When mast cells are
activated, however, HDL molecules are also modified by mast
cell mediators and are then unable to remove cholesterol from
the

foam

cells

(Kovanen

1991) .

Mast

cells

have

been

implicated in cardiac hypertrophy (Rakusan et al. 1990).

A

significantly higher percentage of mast cells was found close
to arteriolar portions of coronary capillaries than one would
expect from their even distribution along the capillary wall.
The increase in cardiac mass and formation of new capillaries
in hypertrophic rat hearts induced by pressure overload is
accompanied by increasing number of mast cells

(Rakusan

&

Campbell 1991) .
Mast cells in other diseases.

Involvement of mast cells

in arthritis has been described extensively (Mican et al.
1990, Gruber 1991).

The number of mast cells are greatly

increased in synovial tissue of patients with rheumatoid
arthritis (Crisp .e.t. 2],,. 1984, Godfreg .e.t. al. 1984, Irani .e.t.
al. 1987, Bridge et al. 1991) and in rat adjuvant arthritis
(Gryfe et al. 1971).

In one study, the severity of antigen-

induced arthritis following adjuvant injection was compared in
mast-cell deficient mice and normal mice with mast cells
(Ma.lone et al.. 1988, Van den Broek et al. 1988).

The results

indicated that mast cells can dictate the acute inflammatory
events

and

potentiate

chronic

changes

of

cartilage

degradation. When purified arthritogenic peptide was injected
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into

rat

knee,
~

(Caulfield

acute
al.

mast

cell

degranulation

The

1988).

event

was

occurred

followed

inflammation, fat necrosis, and fibrin deposition.

by

Tryptase

released f ram mast cell granules may play an important role on
chemotaxis,

cartilage

and

bone

turnover,

and

synovial

fibrosis.
The importance of mast cells in skin has been well
recognized

.eJ... 1990,

(Lawrence~

Church~

gl. 1987, Lowman

al. 1991, Tainsh

gt.

al. 1988, Rothe et

al. 1991).

gt.

Increased

number of mast cells have been observed in the pathogenesis of
et al.
many skin disorders such as atopic dermatitis (Mihm 1976)

I

scleroderma

sclerosis (Hawkins

gt.

(Nishioka et

al.

1987),

progressive

al. 1985), neurofibromatosis (Isaasson

1976, Riccardi 1981, 1987), bullous pemphigoid (Wintroub
al.

1978),

abnormal

wound

healing

such

as

keloid

~

and

hypertrophic scar (Smith et al. 1987), striae distensea (Sheu
et al. 1991), and urticaria (Schwartz 1991).

The pathways in

f ibrotic disorders may rely on the interaction between mast
cells and fibroblasts.

One possible cause of the fibrotic

disease is the increase in collagen synthesis by fibroblasts
(Botstein

gt.

lymphocytes

al. 1982).
such

as

Initially, factors secreted by T
IL-3

can

induce

the

growth

and

differentiation of immature mast cells from bone marrow cells.
However, the progress from the immature cells to mast cellconunitted progenitors depends on stem cell factors produced by
fibroblasts

(Ashman~

Sil. 1991).

Mast cells in turn can
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affect the growth of fibroblasts.

Co-culture of bone marrow-

derived mast cells with mouse 3T3 fibroblasts resulted in the
108 s

of the fibroblast contact inhibition

1989) .

(Dayton et gl.

Tryptase was shown to enhance proliferation of rat and

hamster-derived fibroblasts (Ruess et gl. 1991) .

The action

of mast cells was linked to macrophage, T cells, endothelial
cells, and platelet (Claman 1989).

In lesions of early striae

distensae during puberty, sequential changes of elastolysis is
accompanied by mast cell degranulation, followed by an influx
of activated macrophages,
elastic fibers (Sheu
in ovary

(Jones

Shinohara

et

al.

~

which endocytose the fragmented

al. 1991) .

et al.
1987,

1980,

Mast cells are present

Krishna

Schmidt

et

al.

&

Terranova 1985,
1988,

Drishna

&

Terranova 1991), uterus (Massey et gl. 1991, Tainsh gt. al.
1991), and placenta (Purcell & Hanahoe 1991).

Variations in

the number and extent of degranulation of mast cells in ovary
have been shown to correspond to the oestrous cycle (Schmidt
et al. 1988, Krishna & Terranova 1991).

Uterine mast cells

show a significant negative correlation with years of postmenopause (Drudy et al. 1991).

The functional response of

uterine mast cells to an embryo-derived histamine releasing
factor led to the proposal of a possible role of mast cell in
embryo implantation and menstruation (Finn 1986, Cocchiara et
al. 1988).

Mast cells in the proximity of placenta also led

to speculation about their involvement in pathological process
during pregnancy and parturition (Purcell & Hanahoe 91) .
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Mast cells were identified in the arterial wall of rat
adrenal

gland

and

found

to

modulate

both vascular

and

secretory responses in the intact adrenal gland (Hinson et 2J,..
1988) .

Adrenocorticotropic

hormone

(ACTH)

is

known

to

increase steroidogenesis and cause vasodilation in adrenal
gland.

It has been demonstrated that ACTH stimulates adrenal

blood flow and corticosterone secrection by its action on mast
cells (Hinson

.§..t.

2J,.. 1991) .

In the eye, mast cells found in the conjunctiva were
found to be responsible for ocular anaphylaxis (Allansmith et
al. 1981, 1985, 1989).
Oral erythema multiform is usually caused by Herpes
simplex virus or various drugs.

A recent study revealed that

mast cell numbers in the oral mucosa of patients with erythema
multiform lesions were higher than those in the control
subjects, suggesting that mast cell degranulation occurs in
the

most

intensely

inflamed

area

(Ruokonen

1992).

Participation of mast cells in other oral diseases is also
reflected by the increase in mast cells in oral lichen planus
(Jontell

et 2J,..

1986)

and gingivitis

(Zachrisson 1968).

Tobacco smoke has been shown to cause release of preformed
mediators from canine mast cells (Thomas et al. 992).
An increase in renal tissue mast cell number was detected

in fulminant hepatitis patients with hepato-renal syndrome
(Yoshimura

&

Mori 1991) .

This suggests a role for renal

tissue mast cells in the onset of acute renal failure in liver
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diseases.

The role of mast cell in systemic anaphylaxis and

mastocytosis

is well

documented

(Schwartz .et. al.

1987).

Elevation of mast cell activation correlates with the severity
of anaphylaxis (Matsson
van der Linden

gt.

~

gl. 1992).

gl. 1991, Yunginger

.et. gl. 1991,

In systemic mastocytosis, liver,

spleen, and lymph nodes may be infiltrated by mast cells and
lead to hepatosplenomegaly and enlarged lymph nodes (Metcalfe
1991) .

Extensive involvement of mast cells may result in

liver fibrosis, portal hypertension, and abdominal ascites. In
vitro studies showed that mast cells enhanced the spontaneous
and T-mitogen-induced proliferation of spleen and lymph node
cells (Gushchin et al. 1991).
The involvement of mast cells in the various biological
and pathological situations reviewed above has revealed the
functional significance of mast cells in health and disease.
Investigation of the specific roles of different mast cell
sub-types, although in its juvenile stage, has been considered
very important in the search for more definite answers to the
questions that remain.

2. Mediators
Understanding the mechanism of mast cell action and mast
cell heterogeneity relies, to a great extend, on the knowledge
of mast cell granular mediators.

Mast cell mediators are

generally divided in two groups, preformed mediators and newly
generated mediators (Bernstein & Lawrence 1990, Gordon .et, al.
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19 90, Schwartz & Huff 1991).

The following table lists the

major mediators present in mast cell granules.

Preformed

Newly Formed

Histamine

PGD2

5-HT

Thromboxane

Dopamine

LTB4

Heparin

LTC4

Condroitin sulfate

LTD4

Tryptase

LTE4

Chymase

PAF

Cathepsin G

Cytokines

Carboxypeptidase

TNF-c:Y

VIP

IL-1,2,3,4,5,6,10

SLM

MIP-la
MIP-lfJ
MCAF

TCA3

GM-CSF

TGF-fJ
IF-y
SCF

Abbreviations used above are:

5-hydroxytryptamine

(5-HT);
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vasoactive

intestinal

peptide

(VIP);

somatostatin-like

molecules (SLM); prostaglandin D2 (PGD2); leukotrienes (LT);
tumor necrosis factor
inflanunatory

O!

(TNF-0!); Interleukins (IL) ; macrophage

proteins

activating

factor

(MIP);

(MCAF);

monocyte

chemotactic

and

granulocyte/macrophage-colony

stimulating factor (GM-CSF); transforming growth factor (TGF);
interferon (IF); stem cell factor (SCF); platelet activating
factor (PAF) .
Biogenic
dopamine

amines

can be

such

as

histamine,

secreted from mast

serotonin,

cells

and

(Enerback 1966,

Jenkinson ,gt. al. 1970, Weitzman et al. 1985, Larnbracht et al.
1990) .

Histamine in lung serves as a potent spasmogen which

can cause bronchoconstriction and vasoconstriction.
vasodilator

in

affecting

local

vascular

As a

permeability,

histamine must act via the interaction with cell-specific
receptors Hl and H2 (Schwartz 1991) .
Mast cell proteoglycans includes highly sulfated heparin
and less sulfated condroitin (Stevens et al. 1988, Thompson ,gt.
al. 1988).
released

When degranulation occurs, the proteoglycans are
together

chondroitin

have

with
a

granular

stabilizing

enzymes.
effect

on

Heparin
these

and

enzyme

activities (Schwartz & Bradford 1986, Alter et al. 1987) and
on growth factor activities (Kellen & Lindahl 1991, Ruoslahti
&

Yamaguchi 1991) .

Heparin also has well known anticoagulant

activity (Metcalfe et al. 1981).

Mast cell proteoglycans may

play an important role in initiating binding of LDL and HDL
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molecules in atherosclerosis (Kovanen 1991) .
Tryptase and chymase are neutral serine proteases unique
to mast cells (Schwartz 1990).
are

discussed

above.

The possible roles of tryptase

Chymase

converts

angiotensin

I

to

angiotensin II at a rate 4 times faster than does angiotensinconverting enzyme (Wintroub

1984).

~al.

Other postulated

roles for chymases include involvement in basement membrane
degradation

(Briggaman

et

al.

1984),

production

(Sonunerhoff

ru;.

li-

glandular

1989) ,

degradation (Reilly et al. 1982).

and

mucus

bradykinin

Cathepsin G is a neutral

serine endopeptidase found in neutrophils and monocytes.
cathepsin

G-like

protease

has

also

been

found

A

using

inununocytochemical and enzyme histochemical techniques in mast
cells

al. 1990).

(Schechter~

Carboxypeptidase A is also

localized in mast cell secretory granules (Goldstein et al.
1989).
the

This enzyme preferentially removes amino acids from

C-terminus

of peptides which have

residues or leucine.

terminal

aromatic

Rat mast cell carboxypeptidase A is

similar to bovine pancreatic carboxypeptidase A (Everitt et
al. 1980, Schwartz et al. 1982).

As discussed previously,

mast cells also contain preformed peptides such as VIP (Cutz
et al. 1978), and SLM (Goetzl
Newly
cytokines

formed
(Gorden

mast
et

~

cell
al.

mediators

1990),

metabolites (Peters et al. 1984).
and TNF-a in mast cells

ll· 1985).

(Brown

and

include

various

arachidonic

acid

Since the discovery of IL-4
_gt. g],_.

1987, Young et ll·
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19 97) , many cytokines have been found in activated mast cells.
These include IL-1, IL-3, and IL-6. Transcripts for IL-2, IL5, IL-10, MIPS, MCAF, GM-CSF, TGF-P, IFy, and SCF are also
found in the activated mast cells.

Many of the cytokines can

affect mast cell growth and development.

IL-3, for instance,

can stimulate IL-3 dependent progenitors derived from bone
marrow to progress to mast cell-committed progenitors (Huff &
Justus 1988) .

These progenitors then migrate to fibroblast-

rich sites possibly by binding to laminin through their cell
surface laminin receptors (Thompson et al. 1989) .
other hand,

SCF, on the

can directly stimulate proliferation of

the

cormnitted progenitors and induce granulation of mast cells
(Tsai

~

al.

1991) .

IL-4,

and IL-10 are co-factors for

proliferation and differentiation of mast cells (Hamaguchi et
al. 1987, Gordon

~

al. 1990) .

In contrast to the other

cytokines, GM-CSF and IFy can suppress proliferation of mast
cells

(Bressler

et

al.

1989,

Burd

et

al.

1989).

The

biological significance of some mast cells' ability to release
both negative and positive effectors remains unclear.
Mast cells can incorporate exogenous arachidonic acid
into neutral lipids and phospholipids and store these lipids
in membranes and cytoplasmic lipid bodies (Dvorak i l al. 1983,
Peters

~

~-

1984) .

When

mast

cells

are

activated,

arachidonic acid is release from the lipids and metabolized to
PGD2 and thromboxanes through the cyclooxygenase pathway or to
leukotrienes and lipoxins through the lipoxygenase pathways
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(Schwartz

1987,

Serofim

& Austin

PGD2

1987).

is

a

vasoconstrictor which is released from not only mast cells
(Robinson 1988) but also macrophages (MacDermot et al. 1984),
platelet (Oelz et al. 1977), and CNS neurons to promote sleep
(Hayaishi 1991).
neutrophils,

LTB4 is a potent chemotactic factor for

eosinophils,

monocytes,

and basophils.

Its

ability to attract neutrophils is as strong as complement CSa
(Ford-Hutchinson et slJ...

1980).

LTC4,

LTD4, and LTE4 are

bronchoconstrictors and vasoconstrictors.

In lung where there

are few LTC4 receptors, LTC4 must be converted to LTD4 and
LTE4 to mediate its effects on bronchoconstriction.

LTD4-

receptor antagonists have been shown to attenuate allergicinduced bronchoconstriction (Griffen §.t. al. 1983).

PAF, a

phosphotidylcholine analog, can cause aggregation of platelets
and dilation of blood vessels (Kerdel & Soter 1989).

3. Mast Cell Heterogeneity
Mast cell are not a homogeneous cell population.

The

heterogeneity of mast cells is reflected by their responses to
different

stimuli, the content of secretory granules, and

their phenotypes.
Responses to stimuli.

Mast

cells

from

different

sources were found to have different functional responses to
IL-3.

The growth and differentiation of mast cells from

intestinal mucosa depend on IL-3 while those from connective
tissues are mostly independent of Il-3 (Razin

~al.

1984).
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aowever, the dependency of mast cells on IL-3 depends on the
microenvironment and is interchangeable (Valent

~

gl. 1991) .

When IL-3 dependent mouse mast cells were co-cultured with
fibroblasts, they exhibited a phenotypic change toward IL-3independent mast cells
different

responses

tryptase only)

(Levi-Schaffer~

of

MCr

al. 1986).

(human mast

cells

Data for
containing

and MCrc (human mast cells containing both

tryptase and chymase) to cytokines were derived from tissue
culture and in vivo observations. When cord blood mononuclear
cells are co-cultured with mouse 3T3 fibroblasts, about 80-90%
of the resulting mast cells are the MCTc phenotype (Furitsu et
al.

1989) .

It

has

been known

that

SCF

secreted

from

fibroblasts can stimulate development and growth of rodent
connective tissue mast cells (C™C) . Addition of T lymphocyte
factors to the culture did not alter the result of MCTc cells.
In rodent cell culture, T lymphocyte factors can reverse the
C™C type to mucosal mast cells

(MMC) . These observations

suggest that,

human MCTc type is not T

like rodent C™C,

lymphocyte dependent.
Mast

cells

from

different

differently to specific agents.

sources

often

respond

Secretogogues such as the

calcium ionophore A23187, 48/80, basic peptides (polylysine,
polyarginine), VIP, SP, somatostatin, bradykinin, endorphins,
morphine

sulfate,

degranulation of

and

anaphylatoxin

IL-3-independent mast

csa

can

stimulate

cells while

IL-3-

dependent mast cells such as those isolated from human lung
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respond to A23187 but none of the others
aernstein & Lawrence 1990).

{Church~

gJ._. 1982,

Disodium cromoglycate which is

widely used for treatment of allergic asthma can inhibit
degranulation of mast cells from human intestinal lung mucosa
{Flint

gt_

al. 1985, Schmulzler et al. 1985, Befus et al. 1987)

but can not inhibit degranulation of mast cells from human
skin

(Cl~ggs

et al. 1985).

In contrast to human, disodium

cromoglycate induces degranulation of connective mast cells
but not mucosa! mast cells in rodent {Pearce 1986, Breninstock
1988) .

Mast cells from different sources respond to nerve

growth

factor

{NGF)

differently.

Proliferation

and

differentiation of rat mast cells from cultured blood cells
and spleen cells were enhanced by NGF {Aloe 1977, 1988, Aloe
& Desimone 1989).

Mucosa! mast cells, on the other hand, did

not respond to NGF {Johnson & Krenger 1992).
the gut
infection

appear to be
{Stead~

gJ._.

Mast cells in

ready to defend against parasitic
1987, Arizono et al. 1990).

When

brain tissues were infected by the larval stage of the cestode
taenia solium, brain mast cell numbers did not increase as the
gut mast cells had {Johnson & Krenger 1992).
Differences in mediator content.

of

mast

cells

also

reflects

mast

The mediator content
cell

heterogeneity.

Heterogeneity of proteoglycan content has long been recognized
in different mast cells. Heparin has been found predominantly
in connective tissue mast cells

{Yurt

~

al.

1977) while

condroitin E has been found mainly in mucosal mast cells
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(Eliakim

~

g].,.

1986, Gilead et al. 1987).

The distribution

of chymase and tryptase varies depending on mast cell type and
species (Schwartz et al. 1981a, Woodbury & Miller 1982, Irani
~

al. 1986) .

Carboxypeptidase A has been found in both human

skin and human lung mast cells

(Goldstein et al.

1989,

Reynolds et g].,. 1989) but occurs only in CTMC in the rat
(Everitt

~

.e.i.. 1980, Schwartz

~

al. 1982).

Production of

eicosanoids also reflects mast cell heterogeneity (Kewus
al. 1982, Heavey
al. 1989).

~al.

~

1988, Church et al. 1989, Robinson et

PGD2 is produced predominantly by rat peritoneal

mast cells but is consistently produced by both human skin and
lung mast cells.

LTC4 and LTB4 are produced at a level

significantly higher in mucosal mast cells than in connective
tissue mast cells in the rat. Human lung mast cells produce
approximately nine times more leukotrienes than do skin mast
cells.

The leukotrienes are mainly LTD4 and LTE 4 in human

lung mast

cells as opposed to LTC4

in skin mast cells.

Serotonin is present in mouse peritoneal mast cells (Weitzman
et al. 1985) and brain mast cells (Lambracht et al. 1990) but
not intestinal mast cells (Enerback 1966) .
found in bovine skin mast cells
Protease
different.

contents

of

the

two

Dopamine has been

(Jenkinson

mast

cell

~

types

al.

1970) .

are

also

Cathepsin G, for example, was detected in CMrc but

not in MCr using immunoassay techniques (Meier et al. 1985).
Carboxypeptidase was found at high concentration in MCrc type
from human skin mast cells but in negligible amounts in MCT
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type from lung mast cells based on the activity of enzymatic
hydrolysis of angiotensin (Goldstein
Different phenotypes.

~

al. 1987).

Besides differences in stimuli

response and mediator content discussed above, mast cells
exhibit additional phenotypic heterogeneity

(Galli 1990) .

Mast cells have been found in different species such as in
human,

other manunals,

fish and amphibians

(Michels 1963) .

Marked morphological differences exist between mast cells from
different species as well as between mast cells in different
anatomical locations within a species. The differences are
defined based the properties of histochemical stains which
discriminate mucosal type mast cell from connectives tissue
type mast cells (Enerback 1966).

In the rodent, mucosal type

mast cells tend to be smaller and contain fewer granules than
connective tissue type mast cells (Gleich et al. 1986).

In

the human, mast cells have subpopulations comparable, but less
well defined, than rodent connective tissue type mast cells
and mucosal type mast cells (Otsuka et al. 1985, Eliakim

gt

al. 1986) . Ultrastructural evidence from cytoplasmic granules
reveal striking characteristics unique to either the human MCr
or the MCrc (Craig et al. 1988, 1989, Dvorak et al. 1989).
Under the electronmicroscope, mast cell cytoplasmic granules
exhibit a variety of substructural patterns termed scrolls and
crystals (or lattice features) . Mast cell granules from human
lung are more uniform in shape and have lattice features.
Human skin mast cell granules, on the other hand, have a less
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well

defined

shape

and

show

discrete

scrolls.

rmmunoelectronmicroscopic analysis indicate that the scroll
feature is characteristic of MCr mast cells which contains
only

tryptase

while

the

lattice

or

grating

feature

is

characteristic of MCrc type mast cells which contain both
tryptase and chymase.

Unlike human mast cell granules which

have intricate lamellae and scroll work,

rodent mast cell

granules show a more amorphous appearance under the electron
microscope (Dvorak

~

al. 1983).

Data on morphology, responses to specific stimuli, and
mediator content reveal a marked degree of diversity in mast
cell populations,.

Various mechanisms have been proposed to

account

cell

for mast

heterogeneity

(Galli

1990).

The

mechanisms of cellular maturation and differentiation, changes
associated with functional activation,

and acquisition of

molecules derived from other cell types may contribute to
phenotypic heterogeneity of mast cells by acting alone or in
combination

with

mechanisms,

the

the

other

mechanisms.

demonstration

of

Whatever

different

mast

the
cell

subpopulations continue to elicit great interest due to its
clinical significance.

4. Classification Of Mast Cells
Histochemistry Methods.

Heterogeneity of mast

cells

poses the need for meaningful and reliable methods to identify
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distinct subsets of mast cells which may have functional
differences.

As

discussed above, mast cells are defined based

on their content of large, electron-dense cytoplasmic granules
made

up

of

sulfated

proteoglycans

and

other

mediators.

Mediators are part of the electron-dense granules of mast
cells.

However, many of the mediators are not unique to mast

cells and are not considered proper markers for mast cells.
Prostaglandin, thromboxanes, leukotrienes, and a varieties of
cytokines can be products of other cell types.
biogenic amines and neuropeptides.

So can the

Cathepsin G can be found

in neutrophil and monocytes while carboxypeptidase A can be
found in other cell types in the pancreas.

The mediators

unique to mast cells granules are tryptase and chymase.
Proteoglycans

are

also

part

of

the

electron-dense

granules which consist of many glycoaminoglycans, a chain of
disaccharide

repeating

units

containing

an

amino

derivative such as glucoamine or galactoamine,
linked to a core protein.
found

sugar

covalently

The intracellular proteoglycans

in mast cell granules contain the highly sulfated

heparin and/or the less sulfated condroitin sulfate E (Stevens
et al. 1988, Thompson et al. 1988).

The number of carboxylate

and sulfate groups in the disaccharide units determine the
overall

negative

proteoglycan.

charge

density

of

a

specific

type

of

The average number of sulfate residues in each

disaccharide repeating unit is 2. 5 in heparin and 1. 5 in
chondroitin sulfate E.
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These

differences

histochemical
staining.

in

techniques

charge

are

which utilize

the

basis

metachromatic

for
dye

These techniques were first used to identify mast

cell subsets in rodents (Enerback 1966) .

Metachromatic dyes

are cation dyes such as toluidine 0, alcian blue and safranin

o.

When certain tissue elements are stained with one of the

dyes, the color of the dye changes from blue to a purple or
reddish violet color, i.e. the absorbance of the dye changes
from

a

higher

reaction.

wavelength

to a

lower wavelength

in

the

The change in color is called metachromasia.

The

tissue elements capable of inducing metachromasia are called
chromotropes and are usually polyanions such as heparin and
chondroitin. The dyes resulting in metachromasia are called
metachromatic dyes. The chemical theory of metachromasia has
been discussed (Schubert & Harnberman 1956) .

Metachrornatic

dyes contain chromophobic groups which exist in two tautomeric
forms in a resonance system.
energy level for the
characteristic

1f

Each tautomeric form has its own

electrons and absorbs light of a

wavelength.

A reversible

equilibrium between the two tautomeric
results

in

a

color

change.

It

has

shift

forms
been

in

the

of the dye
found

that

polymerization of metachrornatic dyes results in a shift of the
equilibrium of the molecular species in the resonance system.
Chromotropes with their negative charges close together can
bind cationic metachrornatic dyes through salt bridges.

The

binding brings the dye molecules into close contact which
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initiates polymerization.

These shifts the peak absorption

spectra to a shorter wavelength resulting in

metachromasia.

Alcian blue 8 GX is a metachromatic dye containing four
isothiouronium groups (Scott 1972).

Alcian blue differs from

other proteoglycan stains in that it does not stain nucleic
acids and has a high solubility even in the presence of high
salt concentrations.

At pH 2.5-2.7, alcian blue stains both

sulfated and non-sulfated proteoglycans, giving a blue color.
At pH 1, only the sulfated glycosaminoglycans are stained
(Pearse 1968).

Safranin O is a metachromatic dye used to

stain highly sulfated proteoglycans such as heparin.

The less

sulfated condroitin sulfate does not bind safranin O well.
Together with alcian blue, safanin has been used to identify
rodent mast cell types based on their metachromatic staining
properties (Enerback 1966).
Utilizing

those

properties

of

the

chromotropes

and

metachromatic dyes, Enerback and others demonstrated two types
of mast cells in rodent
1972).

(Enerback 1966, Miller

&

Walshaw

In these experiments, mast cells in different tissues

were fixed, and stained first with alcian blue and then with
safranin

stain.

It

was

found

that

mast

cells

in

the

intestinal lamina propria were stained blue with the alcian
blue but remained blue upon subsequent staining with safranin.
On the other hand, mast cells in the skin and peritoneal
cavity turned red after double staining indicating staining by
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safranin.

These observations resulted in the classification

of rodent mast cells into two subtypes, the mucosa! type mast
cells (MMC) from the intestinal mucosa! and the connective
tissue type mast cell (CTMC) from skin and peritoneal lavage.
subsequent experiments found that these two types of mast
cells

appeared

including

the

pharmacological

to

exhibit

response
agents

discussed above.

The

as

differences
to

in

cytokines

well

as

many

aspects

and

various

mediator

content

terms MMC and CTMC ref er

to

as
the

phenotype rather than the tissue location of mast cells
because each of

them may be

found both in mucosa!

and

connective tissue sites.
Histochemical techniques relying on the metachromatic
dyes has limitations which can not be over emphasized.
observed earlier (Combs et al. 1965),

As

inunature CTMC cells

exhibit MMC staining properties presumably due to their lack
of heparin.

In contrast to rodent mast cells which have

distinct proteoglycan content in the majority of the two mast
cell subtypes, human mast cells isolated from both skin and
lung have heparin proteoglycans as measured (Metcalfe gt al.
1979, Metcalfe et al. 1980, Eliakim et al. 1986, Stevens et
al. 1988, Thompson gt al. 1988).

The presence of heparin in

the two potentially different types of mast cells abolishes
the

discriminating

basis

for

the

metachromatic

staining

techniques in human.
Immunohistochemistry.

Immunohistochemical techniques
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have become the tools of choice in the recent years to
identify subtypes of mast cells in the human and rodent (Irani
~

al .

19 8 6,

Gibson

gt_

al.

19 8 7) .

The techniques uses

tryptase and chymase of mast cell granules as the pref erred
markers. Trypsin-like activity was originally demonstrated in
human mast cells by histochemical techniques (Glenner & Cohen
1960, Chiu & Lagunoff 1972).

Tryptase has been found to be

the principal enzyme accounting for the trypsin-like activity
in human mast cells (Schwartz et al. 1981a).

The amount of

tryptase found in human mast cells (10-35 pg/cell) accounts
for 20-50% of the total protein in the cells (Schwartz et al.
1981b) .

In contrast to mast cells, only a negligible amount

of the enzyme (<0. 04 pg/cell) was measured in human basophils.
No detectable amount of tryptase has been measured in other
cell

types

in normal

skin,

lung bowel,

and eosinophils,

neutrophils, monocytes, or lymphocytes from peripheral blood.
Sequential

staining with alcian blue

followed by either

immunoperoxidase or immunofluorescence using a monoclonal
murine anti-tryptase antibody showed a one-to-one correlation
between anti-tryptase-positive cells and alcian blue-positive
cells, which means that all cells with tryptase are mast cells
as demonstrated by the metachromatic property (Schwartz 1985).
Results

from electron microscopy showed tryptase-positive

stain in immature mast cells which have newly formed granules
(Craig et al. 1989).

Evidence also indicated that tryptase

appears in cultured human fetal liver mast cell granules prior
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to the acquisition of their metachromatic properties (Irani &
Schwartz 1990} .
selective

and

Thus, tryptase has been chosen as a highly
specific marker for

human mast

cells.

In

dispersed human foreskin mast cells, a substantially lower
amount of chymase (94.5 pg/cell} was found in comparison to
tryptase in the same cell type ( Irani et al. 1986}.

Based on

the specific location of the enzymes, tryptase and chymase
have been convincingly applied to classification of mast cell
subtypes in humans.
The presence of chymase activity in rat mast cells was
also demonstrated some time ago by histochemical techniques
(Benditt

&

Arase 1959} .

Two types of chymase have been

located in rat mast cell granules

(Miller et al.

1990} .

Chymase I is found exclusively in CTMC-type and chymase II in
MMC.

The amount of chymase I

about

25%

of

the

(24-30 pg/cell} accounts for

total proteins

(Schwartz et al. 1981).

in the

CTMC

type

cell

An equivalent amount of chymase II

(26 pg/cell} was found in cultured MMC (Haig et al. 1982).
Using human lung, skin, and small intestine fixed in
Carney's

solution,

Irani's

group

(Irani

demonstrated two distinct human mast cell

et

al.

1986}

types using a

polyclonal rabbit anti-chymase and a monoclonal murine antitryptase antibody.

First, they performed single staining in

adjacent tissues.

The results showed that all mast cells

stained tryptase-positive.

However, only skin, intestinal

submucosal, and peribronchial mast cells, but not intestinal
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mucosal or lung alveolar mast cells, stained chymase positive.
These results indicated the presence of different mast cells
based on their protease content.
that

those

cells

with

Second, in order to confirm

chymase

also

contain

tryptase,

simultaneous double labelling experiments were performed by
incubating the two antibodies simultaneously with the same
sections.

Then chymase-positive cells were stained blue using

an alkaline phosphatase reaction followed by staining of
tryptase-positive cells using peroxidase.

The results showed

that all cells that first stained blue turned dark brown
following the subsequent stain suggesting that chymase truly
co-resides with tryptase in the same cell (Irani et al. 1989}.
Finally, in order to demonstrate the presence of two distinct
mast cell types in the same tissue section, sequential double
labeling experiments were performed.

Sections were first

incubated with the anti-chymase antibody, and developed to
give clusters of brown color which happen to interfere with
the

subsequent

incubated

with

stain.
the

The

sections

anti-tryptase

were

antibody

subsequently
followed

development of the alkaline phosphatase blue stain.

by

Cells

containing chymase remained brown while those with tryptase
but without chymase were stained blue.

The results confirmed

the existence of the two types of mast cells.

Human mast

cells were therefore divided into two subtypes, the MCT type
which contains tryptase only, and the

M~c

type which contains

both tryptase and chymase. Using a newly developed monoclonal
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murine anti-chymase antibody and the murine anti-tryptase
antibody, Irani

~

gl. confirmed their previous findings in a

varieties of human tissues (Irani
Electron

microscopic

~

evidence

al. 1989, 1990).
also

provided

strong

support for the classification of the two human mast cell
types.

Ultrastructural

studies

using

double

immunogold

staining procedures showed that all granules in MCrc cells
contained both tryptase and chymase and that the MCr cell
granules had only tryptase (Craig et al. 1988).

Subsequent

studies based on enzyme activity assay, mediator contents, and
the response of the MCT and MCTc types to cytokines showed
differences between the two types of human mast cells.
Synthetic substrates are also available for detection of
tryptase and chymase activities in tissue sections (Osman et
al. 1989).

The experiments likewise showed tryptase activity

in all mast cells in human intestine while chymase activity
was detected only in the submucosal mast cells. Mast cells
with chymase activity also demonstrated tryptase activity.
Thus, the intestinal mucosa! mast cells are predominantly MCT
type while the submucosal mast cells are MCTc type.

These

observations confirm the distinction between the two mast cell
types based on immunohistochemical results.
The two different mast cell types have been related to
different diseases.
affecting

T

cell

In patients with congenital disorders
functions

or

with

AIDS

and

combined

immunodeficiency, a significant decrease in the MCT type was
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detected from the analysis of gastrointestinal tissues of the
patients while the MCn; type was virtually not affected (Irani
~

gl. 1987a).

In synovium of rheumatoid arthritis subjects,

where heavy lymphocyte infiltration occurs, a mixture of MCr
and MCrc types were found while usually only MCrc type is
present in the normal synovium (Irani et al. 1987b).
observation
lymphocyte

indicate
factor

that

activity of

dependent.

The

MCr

cells

significance

These
may be
of

the

innnunohistochemical techniques is also demonstrated by the
ability to distinguish the two subtypes in immature human mast
cells.

Coupled with electron microscopy,

Craig's

group

observed that the amount of MCr and MCTc found in immature mast
cells in various tissues are parallel to those found in the
counter part of the mature mast cells {Craig et al. 1989).
In rat, immunohistochemical techniques have targeted two
different forms of rat chymases found in rat mast cells,
chymase I and chymase II {Gibson et al. 1987, Huntley et al.
1990).

In the experiments, polyclonal monospecific rabbit

anti-chymase I and monoclonal mouse anti-chymase II were used.
Adjacent sections of tissues from various sources were stained
individually

with

anti-chymase

I,

anti-chymase

II,

and

metachromatic dye such as toluidine blue or alcian blue and
safranin 0.

Populations of stained cells were counted and

compared to the adjacent sections.

A correlation was then

drawn

results

between

the

sections.

The

provided high

correlation of the chymase I-positive cells with the CTMC type
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defined by the metachromatic properties and the chymase IIpositive cells with MMC.

Although some overlap of chymase

r-

and chymase II-positive cells were observed, the population of
the cells is very small.

A minor population of the chymase !-

positive cells were shown to be MMC type in both nonmucosal
and mucosal

tissues.

The

results

suggest

that

granule

protease phenotyping can be an alternative techniques in
identifying mast cell subsets in rodent system.
Although tryptase has been purified from rat tissues, no
information is available regarding its distribution among rat
mast cells.

5. Purposes Of The Project
As reviewed above, mast cells play an important role in
health and diseases.
mechanisms

However, investigation of the specific

involved

in

mast

cell

functions

has

complicated by the existence of mast cell heterogeneity.

been
Rat

is one of the major sources of our knowledge about mast cell
functions.

Thus

it

is

very

important

to

identify

heterogeneity of rat mast cells for interpretation of data and
comparison to the human system.

Successful identification of

human mast cell types suggested the possibility that rat mast
cell

types

could

be

distinguished

in

a

similar

way.

Demonstration of chymase I-positive and chymase II-positive
rat mast cell types provided a basic reference for detecting
rat mast cell types based on the contents of their neutral
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proteases.
A tryptase has been purified and characterized from rat
skin in our lab.

It was our goal to raise a polyclonal anti-

rat tryptase antibody and localize the enzyme in rat skin,
lung, peritoneal lavage cells, and small intestinal mucosa.
To do this, antibody specificity would first be evaluated by
ELISA and Western Blot using the purified tryptase as antigen.
rmrnunohistochemistry techniques would be used to identify mast
cells

containing

tryptase

and/or

chymase.

Mast

cell

distribution in the tissues would be evaluated with the
metachromatic dyes,

Single

alcian blue and safranin O.

staining with alcian blue, anti-tryptase, and anti-chymase I
antibodies would provide data for distribution of total mast
cells,

tryptase-containing

mast

cells,

and

chymase

containing mast cells, respectively, in the tissues.

I-

Double

staining with metachromatic dye followed by anti-tryptase or
anti-chymase I would confirm the existence of the proteases in
At the same time, it would

the metachromatic mast cells.
allow

correlation

between

the

CTMC

and

MMC

tryptase-positive or chymase I-positive cells.

types

with

In order to

verify if tryptase and chymase I co-reside in the same cell,
simultaneous double labeling would be performed by labeling
the tissue sections with both anti-tryptase and anti-chymase
I

antibodies

simultaneously

followed

corresponding colors one after the other.

by

developing

the

As a confirmation

of the existence of two distinct mast cell types,

tissue

105

sections would be labeled with the anti-tryptase antibody
first followed by color development.

Then the sections will

be labeled a second time with anti-chymase I antibody to
confirm the distinct types of mast cells based on the presence
of the enzymes.

CHAPTER VIII
MATERIALS AND METHODS
A. Materials
Alcian blue SGX, safranin 0, diaminobenzidine, 3-amino-9ethylcarbazole,

~02

(30%), and peroxidase-conjugated rabbit

anti-goat IgG were obtained from Sigma Chemical Co.,

St.

Louis, MO, Molecular weight standards were from Pharmacia,
Piscataway, NJ and peroxidase-conjugated swine anti-goat IgG
from Boehringer Mannheim, Indianapolis, IN.

Rabbit IgG anti-

chymase I had been made specific for chymase I by adsorption
with chymase II and affinity purification with chymase I
(Gibson & Miller 1986) .

Tryptase used for immunization and

various immunochemical procedures was purified to homogeneity
from rat skin as described (Braganza & Simmons 1991).

Lung,

skin and peritoneal cells were from normal Sprague Dawley
animals; bowel was taken 14 days after infection of Lewis rats
with Nippostrongylus brasiliensis (3000 organisms/animal) as
described previously (Befus & Bienenstock 1979) to amplify the
number of mucosal mast cells in the intestine.

Samples of

lung, skin and bowel fixed in Carnoy's fluid for 24 hours and
then transferred to absolute ethanol.
in paraffin.

Tissues were embedded

Sections of lung and bowel tissues were 4 µ,

while those for skin was 5 µ.
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Rat peritoneal cells were
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collected from the lavage with PBS solutions {Appendex E) and
subjected to cytocentrifugation.

Each slide contained 2 x 104

viable cells.

B. Methods
1. Western Blot
Protein extracts were prepared from rat skin {10 g),
lung, {2.3 g), bowel {2.5 g), and peritoneal cavity cells {4

x

107 cells) . In the case of skin, cutaneous muscle and fat

layer were removed and the fur was clipped away as close as
possible to the dermis.

The lung and bowel tissues were

rinsed well with tap water followed by MQ water.
were cut into small pieces before extraction.

All tissues

The skin tissue

was homogenized at a 1:9 {w/v) ratio in the homogenization
buff er {Appendix D) using a Polytron homogenizer at full speed
for three 15 second on-off intervals.

The lung and bowel

tissues were homogenized at 1: 5

ratio in the same

buffer.

{w/v)

Peritoneal lavage cells were ultrasonicated for three

20 second pulses on ice.

The homogenate was centrifuged at

18,000 xg for 40 minutes at 4 °C.

The supernatants from the

tissue extracts were stored at -20 °C after assaying for
tryptase activity.

The skin and peritoneal

extracts were subjected to TCA precipitation.

lavage

cell

Extract {500

µl) was mixed with an equal volume of 20% TCA {Appendix D) and
kept on ice for 5 minutes.

The proteins were precipitated by

centrifugation at 4 °C for 10 minutes.

The pellet was rinsed
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with 500 µl of acetone twice.

After air drying, the pellet

was

the

resuspended

in

5

of

µl

SOS-PAGE

sample buffer

(Appendix B) .
The crude extracts were assayed for tryptase and chymase
activities.

The tryptase assay reaction contained 850 µl of

the tryptase assay buffer (Appendix A), 50 µl of the crude
extract, and 100 µl of 10

mM

BAEE (Appendix A) .

was monitored at 253 nm for 5 minutes.
was estimated using a

The amount of tryptase

specific activity of 160 units/mg

protein in the formula presented in Part I.
reaction

contained

The reaction

500

µl

of

the

chymase

The chymase
assay

buffer

(Appendix D), 33 µl of the crude extract, and 467 µl of the 1
mM

BTEE (Appendix D).

The reaction was monitored at 256 nm

for 5 minutes.
Protein

concentrations

of

the

crude

extracts

were

determined using protein assay reagent A and B from Pierce
Chemical Company,

Rockford,

Illinois.

The assay reagent

consisted of 1:50 ratio of reagent A:B.

Each microtiter well

contained 10 µl of the sample and 200 µl of the reagents.
Five BSA concentrations of 25, 100, 200, 300, and 500 µg/ml
were used as standards.

Color development was allowed to

continue at 37 °C for 30 minutes.

Protein concentrations were

measured at 562 nm on a Micoplate Reader.

The standard

protein concentrations were plotted against the absorbance
values.

Sample protein concentrations were determined using

the regression equation derived from the standard curve.
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Western blot was performed as described (Towbin
1979,

Bollag & Edelstein 1991).

~

gl.

The protein samples were

separated in SDS homogeneous 12.S PhastGel using PhastSystem.
Each lane was loaded with 20 µg of the protein extracts or
purposely over-loaded with 30 µg of the extracts to evaluate
any

nonspecific

identical
condition.

gels

binding
were

activity

run

of

the

simultaneously

antibody.
under

the

Two
same

The samples were separated using the following

program:

Separation Program 2

Sample Appl. Down At

2.1

1 vh

Sample Appl.

2.1

10 vh

Sep. 2.1 250 v
Sep. 2.2

Up At
10

50 v

mA

0.1 mA

3

w

0.5 w

15 °C
15

~

60 vh
0 vh

After the separation, one gel was subject to coomassie blue
stain using the following development program:

Development Program 2
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steps

In-port

Out-prot

Time

Temp.

{min)

{°C)

2.01

4

0

10

50

2.02

2

0

5

50

2.03

2

0

8

50

2.04

2

0

10

50

2.05

9

0

5

50

where in-port 4 connects to the stain solution {Appendix D);
in-port 2 connects to the destain solution {Appendix D); inport 9 connects to the preservative solution {Appendix D) ; and
out-port O connects to the waste collection bottle.
The companion gel was used for blotting.

A nitrocellulose

membrane {0.45 µm), six pieces of blotting paper, and the gel
were soaked in a PhastTransfer buffer
minutes.

{Appendix D)

for 5

Then, the gel was clamped to a mounting block and

separated from the plastic gel backing.

The nitrocellulose

membrane was carefully laid on the gel in order to remove the
gel from the plastic backing.

The transfer sandwich consisted

of 3 pieces of the wetted blotting paper at the bottom, the
nitrocellulose membrane with the gel attached to the upper
side, and, on the top of the sandwich, another 3 pieces of the
blotting paper soaked in the transfer buffer.
electrophoretic

transfer was

performed on a

system using the following program:

A semi-dry
PhastTansfer
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separation Program 3

sample Appl. Down At

3.0

0 vh

sample Appl.

3.0

0 vh

Up At
25 mA

20 v

Sep. 3.1

1

w

15 °C

5 vh

Blotting one gel requires 15-20 minutes.

A longer time of 30-

40

blotting

minutes

may

simultaneously.

be

necessary

when

two

gels

After transfer, the nitrocellulose membrane

was pealed off the gel

carefully,

rinsed in the transfer

buffer and dried briefly between 2 pieces of the 3 mm paper.
The nitrocellulose membrane was blocked in 12 ml of the
blocking buffer {Appendix D} in a Seal-A-Meal plastic bag for
1 hour with gentle rocking.

After blocking, the membrane was

rinsed briefly with TBS {Appendix D} three times and incubated
with the goat anti-rat tryptase antibody overnight at 4 °C
with gentle rocking.

The antibody concentration was 5 µg/ml

in O. 5% BSA/TBS solution {Appendix D} .

After washing with TBS

for 10 minutes three times at room temperature, the membrane
was

incubated with 12 ml

of the second antibody solution

{Appendix D} for 2 hours at room temperature and washed again
with TBS for 10 minutes for three times.
fully developed in the

AEC/~02

When the color was

solution

{Appendix D},

the

reaction was terminated by rinsing the membrane with tap water
briefly followed
Finally,

the

by rocking

membrane

was

in MQ water
dried

on

for
3

mm

30 minutes.
paper

and
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photographed.

2. Tissue Section Preparation
Skin, bowel, and lung tissues from Sprague Dawley rats
were fixed in Carney' solution {Appendix B) and embedded in
paraffin wax by Dr. G. Newlands and Dr. S.S. Craig in the
Medical College of Virginia.

The bowel tissue was obtained

from N. Brasiliensis-infected animals.

Sections of lung and

bowel {4 µm) and skin (5 µm) were prepared.
Rat

peritoneal

lavage

cells

were

obtained

modification of the method of Saeki (Saeki 1964).

by

a

Animals

were decapitated with an animal guillotine, and exsanguinated.
Fifteen milliliters of PBS/Heparin buffer (Appendix B) were
injected into the peritoneal cavity.

The abdominal wall was

massaged gently and the body was turned around a few times.
The fluid was collected by cutting along the midventral line
of the abdomin and flipping the opening downward into a
funnel.

Peritoneal lavage cells from two rats (30 ml) were

spun down at 1,000 rpm in a swinging rotor for 10 minutes at
room temperature and resuspended in 5 ml of PBS/DNase buffer
(Appendix B) .

Viable cell concentration was determined in the

following manner.

Cells were first stained with Trypan at a

1:1 ratio of cell/trypan (v/v) in which intact cells remained
colorless while dead cells turned blue.

The number of viable

cells was counted under a microscope using a 25 grid counting
chamber.

The concentration of the peritoneal lavage cells was
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calculated using the following formula: N x D x 104 = C
where N is the number of the viable cells counted in the 25
grid area;

D is

the

total dilution factor

of

the

cell

solution; and C is the final concentration in number of viable
cells/ml.

About 2 x 104 peritoneal lavage cells were adhered

to each slide by centrifugation at 600 rpm for 6 minutes at
room temperature using a cytospin centrifuge.
Before staining,
lavage

cells

was

the cytospin slide with peritoneal

fixed

in

Carney's

solution

at

room

temperature for 15 minutes and washed in HzO for 5 minutes.
The paraffin embedded sections were dewaxed and rehydrated
before staining.

The sections were first dewaxed in three

changes of xylene, 5 minutes each.

Then, they were submerged

through two changes of 100% ethanol for 5 minutes and 3
minutes respectively.

Endogenous peroxidase was inactivated

by incubation of the sections with a Hz02 /methanol solution
(Appendix E)

for 30 minutes.

rehydrated through 95%,

80%,

Finally,
70%,

the sections were

and 50% ethanol for 5

minutes each, and then in MQ water for 3 minutes.

3. Histochemical Stain
Alcian blue was used to identify mast cells in the
tissues.

A rehydrated section was stained in 0.1 ml of 0.5%

of alcian blue solution (Appendix F) for 30 minutes at room
temperature.

The alcian blue was rinsed off the section

gently with MQ water.

A drop of 90% glycerol from a needle
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was laid on each section and then covered with a piece of the
cover glass.

If a second stain were to follow, the cover

glass was placed lightly on top of the section.

For long term

storage, excess glycerol was pressed out of the cover glass
and wiped away with a piece of Kimwipe.
Safranin O was used to stain the connective tissue type
mast cells.

A rehydrated tissue section was stained with 0.1

ml of a 0.1% safranin solution (Appendix F) for 5 minutes at
room temperature.
water,

After rinsing off the safranin with MQ

the section was mounted either to glycerol when a

second stain was

required or to permount

for long term

storage.
Alcian blue/safranin double stain was used to evaluate
the distribution of the CTMC and MMC types of mast cells in
the tissues.
blue.

A tissue section was first stained with alcian

After rinsing off the alcian blue a few times with MQ

water, the section was mounted in 90% glycerol and lightly
covered with a piece of the cover glass.

Different fields in

the section were photographed under a microscope.

The slide

was soaked in water at 37 °C for 10-30 minutes to remove the
cover glass.
was

dried

Following a second safranin stain, the section
thoroughly

in

air

and

mounted

to

permount.

Photomicroscopy was performed on the same fields taken after
the alcian blue stain.

4. Inununohistochemical Stain
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.s_ingle Stain

A goat anti-rat tryptase antibody generated in

or. L.B. Schwartz' lab was used to localize tryptase in lung,
skin,

bowel,

and peritoneal

lavage

cells.

A series

of

dilutions from a stock of 29 mg/ml was used to titer the goat
anti-rat tryptase antibody.
20,

16,

15, 10,

5,

The stock was diluted to 29, 23,

1, and 0.5 µg/ml in PBS/BSA solution

(Appendix F) . The rehydrated tissue sections were blocked for
non-specific binding of the second antibody with O.1 ml of the
normal serum from the same species as the second antibody for
2-3 hours at room temperature.

Then the sections were washed

in MQ water for 2 minutes and incubated with the anti-tryptase
IgG at the above dilution overnight at 4 °C in a moisture
chamber.

The next day, the sections were rinsed gently with

MQ water and washed through 3 changes of TTBS (Appendix F) for
5 minutes each and then with MQ water for 2 minutes.

A 1:50

dilution of the peroxidase-conjugated swine anti-goat IgG was
incubated with the sections for 1 hour at room temperature.
Washing the sections through 3 changes of TTBS for 5 minutes
each and one change of water was sufficient to rinse the
unbound IgG away before the color reaction.

Reddish brown

color for the stained cells appeared after incubation of a
section with 0.1 ml of the AEC/Hz02 solution (Appendix F) for
7 minutes at room temperature.
with

water

and

mounted

in

The sections were then rinsed
90%

glycerol.

The

optimal

concentration was determined from the titration experiments
and used for all of the other experiments.

In the anti-rat
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tryptase stain experiments, a goat anti-rat chymase I antibody
was used as a positive control for all the tissues tested.
preimmune goat IgG which was collected before the goat was
primed with rat tryptase provided a negative control for the
Both the positive and negative

anti-tryptase experiments.

experiments used the same procedure described above except
that the anti-tryptase IgG was replaced with either the antichymase in the positive or the preimmune goat IgG in the
negative controls.
A polyclonal

rabbit anti-rat

chymase

I

monospecific

antibody was used to locate rat chymase I in the tissues.

A

stock solution of 80 µg/ml was diluted into 1.6, 3.2, and 10

µg/ml and titered for its optimal concentration on rat lung,
skin, bowel, and peritoneal lavage cell preparations.

A 1:50

dilution of peroxidase-conjugated goat anti-rabbit IgG was
used as a second antibody.
Double Staining.

Alcian

blue/tryptase

sequential

stain

combined the single staining procedure for the two stains
together.

The rehydrated sections were stained with alcian

blue first.

After performing photomicroscopy, the section

were stained for rat tryptase.

Cells which contained tryptase

changed their color from blue after the alcian blue stain to
brown following the tryptase stain using AEC.

Finally, the

sections were mounted on 90% glycerol and the same fields were
photographed.
Safranin/tryptase sequential stain must be performed by
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staining the tissue with safranin first and then staining for
tryptase.

The red color from the safranin stain disappeared

during the subsequent tryptase stain.

Likewise, the tryptase

staining procedure somehow prevented the tissue from getting
stained by safranin.

Unlike in the alcian blue/tryptase

stain, safranin/tryptase stain used

DAB/~02

substrate for the color development.

Cells stained red by

saf ranin would turn dark brown after the
the cells contained tryptase.

(Appendix F) as

DAB/~02

reaction if

The disappearance of the red

safranin color in fact provided easy identification of the
positive cells in the second stain.
Alcian blue/chymase I sequential stain basically followed
the same procedure as the alcian blue/tryptase stain except
that after alcian blue stain, the sections were blocked with
normal goat serum for 3 hours.

The primary antibody used was

the rabbit anti-rat chymase I IgG.

The second antibody

was

a 1:50 dilution of peroxidase-conjugated goat anti-rabbit IgG.
AEC/~0 2

was used as the substrate for the color reaction.

Simultaneous Double Labeling With Anti-Tcyptase And AntiChymase I Antibodies.

The prepared sections were blocked

with normal swine serum at room temperature for 3 hours.
After rinsing with MQ water, the sections were incubated with
5 µg/ml of the goat anti-tryptase antibody and 3.2 µg/ml of
the rabbit anti-chymase I antibody simultaneously at 4 °C
overnight.

The antibodies were washed away through 4 changes

of TTBS, 5 minutes each, and one change of MQ water.

A 1:50
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dilution of alkaline phosphatase-conjugated swine anti-goat
IgG was incubated for 1 hour with the sections in the presence
of

o. lt of normal rabbit serum.

The normal rabbit serum

prevented swine anti-goat IgG from binding nonspecifically to
the rabbit anti-rat chymase I.

The sections were washed

through 3 changes of TTBS and one change of MQ water again,
and then developed in the Naphthol/Fast Blue solution in the
dark until the blue stained cells were clearly seen under the
light microscopy.

Tryptase-positive cells which stained blue

were counted and photographed. To identify chyma.se I-positive
cells, the sections were incubated with peroxidase-conjugated
goat anti-rabbit IgG at room temperature for 1 hour and then
developed in

AEC/~02

solution.

Blue cells which contained

tryptase turned dark brown indicating that chyma.se I resides
in the same cells as does tryptase.
same fields was repeated.
to the samples.

Photomicroscopy of the

Four controls were run in parallel

Instead of using both antibodies, the first

one contained only goat anti-rat tryptase antibody without the
rabbit anti-chyma.se I antibody.

This control would verify

whether the second peroxidase-conjugated goat anti-rabbit IgG
might cross-react with the goat anti-tryptase antibody.

The

second control was the opposite to the first. It contained
only the rabbit anti-chymase I antibody without the goat antitryptase antibody.

This control would reveal any nonspecific

binding of the alkaline phosphatase-conjugated swine anti-goat
IgG to the rabbit anti-chymase I antibody in the presence of
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o .1% normal rabbit serum. The third control contained neither
one of the two primary antibodies but MPC-11, a murine myeloma
IgG, kappa, which has no known antigenic specificity.

Any

nonspecific binding of either one of the secondary antibodies
to IgG would be detected under this control.

In the fourth

control, the two primary antibodies were replaced by PBS/BSA
to see if the secondary antibodies may bind nonspecif ically to
the tissues.
sequential Double Labeling With The Anti-Tryptase and AntiChymase I Antibodies.

Tissue sections were blocked with

normal swine serum for 3 hours and rinsed with MQ water
briefly.

The first overnight reaction contained 5 µg/ml of

goat anti-tryptase antibody in the PBS/BSA solution incubated
with the sections at 4 °C.

After washing with three changes

of TTBS, 5 minutes each, and one change of MQ water the next
day, the sections were incubated with peroxidase-conjugated
swine anti-goat IgG at room temperature for 1 hour.

The color

reaction was developed in AEC/H20 2 solution as described above.
Then,

the slides were mounted lightly in 90% glycerol and

photographed.
37 °C.

The cover glasses were removed in MQ water at

In the second overnight reaction, the tissues were

incubated
antibody.

with

3.2

µg/ml

of

the

rabbit

anti-chymase

I

The next day, the antibody was washed away with

three changes of TTBS and one change of MQ water again.

After

an one-hour incubation with alkaline phosphatase-conjugated
goat anti-rabbit IgG, the sections were washed with TTBS and

120
MQ water and then developed in the Naphthol/Fast Blue solution
for 15 minutes in the dark.

Photomicroscopy of the same

fields were then performed.

Tryptase-positive cells were

stained reddish brown by AEC.
blocked the subsequent stain.

The color deposit somehow

As a result, any cell staining

blue after the second stain indicated the presence of chymase
I alone in the cell.

5. Photomicroscopy And Calculations
Photomicroscopy was performed with a Zeiss Ultraphot
microscope {Carl Zeiss, Inc., Thornwood, N.Y.) using Kodak
Ektachrome 64T films.

For reflected light photomicroscopy, a

didydium filter and a TIFFEN 49 nun, 82 °C filter were used.
For phase contrast, only the didydium filter was used.

The

pictures were taken at either 160 x magnification using a 40
x oil lens or 250 x using a 63 x oil lens.
Assessment of tissue surface area was obtained with a
Zeiss

Videoplan apparatus.

In

peribronchial areas were measured.

lung sections,

only

the

In the bowel sections,

more than a dozen of the randomly selected areas were measured
and positive cells counted.

In skin, the area of a whole

section was usually included.

Mast cell concentrations were

determined as described previously (Irani et

§l..

90):

Mast Cells/nun3 = [Mast Cells/nun2 ] x [10 3 / { 10 µm + 4 µm)]
where 10 µm was used as an estimate of the average mast cell
diameter and 4 µm was the tissue thickness for lung and bowel;
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s

µm was used for the thickness of skin.

CHAPTER IX
RESULTS

1. Specificity Of Goat Anti-Rat Tryptase Antibody
To examine the specificity of the anti-tryptase IgG,
western blots were perf armed as shown in Figure 12.
show the results of the Western blot;

Lanes 1- 4

lanes 5-8 show the

Coomassie blue stain of an identically prepared gel run in
parallel.
extract

Lanes 1 and 8 each contained 20 µg of the initial
from

rat

skin

and

100

ng

of

purified

tryptase;

respective lanes 2 and 7 were identical except for lack of
purified tryptase.

Lanes 3 and 6 contained 20 µg of the crude

protein extract from rat peritoneal lavage cells.

Lanes 4 and

5 contained 20 µg of the crude extract from rat lung.

Amounts

of tryptase in these extracts was estimated based on the
specific activity of the enzyme purified from skin and the
enzymatic activity in each extract using benozyl-arginine
ethyl

ester.

In each case there was

tryptase applied to the gel.

less

than 1 ng of

The sensitivity of the Western

blot technique for purified tryptase was approximately SO ng;
approximately 500 ng tryptase were needed for detection by
Coomassie

blue.

Accordingly,

tryptase

was

detected

inununologically in lane 1, but not in lanes 2, 3, and 4.
results do show a lack of binding to
122

The
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Figure 12. Specificity Of Goat IgG Anti-Rat Tryptase.
A
Western blot
{lanes
1-4)
and
Coomassie
blue-stained
polyacrylamide gel {lane 5-8) containing extracts of skin
(lanes 1, 2, 7 and 8, 20 µg protein/lane), peritoneal cells
{lanes 3 and 6, 20 µg protein/lane) and lung {lane 4 and 5, 20
µg protein/lane) . Purified rat tryptase was included in lanes
1 and 8 {100 ng/lane). Molecular weight standards used
included phosphorylase b {94,000), albumin {67,000), ovalbumin
(43,000), carbonic anhydrase {30,000), ~1-trypsin inhibitor
(20,100), and ~-lactalbumin {14,400) {Pharmacia).
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the numerous other proteins present in each tissue extract,
indicating a high degree of specificity for tryptase.

2. Distribution Of Mast Cells And Tryptase Positive Cells
The distributions of connective tissue (red) and mucosal
(blue) types of mast cells by staining with alcian blue and
safranin, and tryptase-positive cells by immunohistochemistry
were determined in comparable sections of skin, bowel, and
lung and in cytospin preparations of peritoneal cells.

In

lung, mast cells were detected primarily in peribronchial
tissue, 53% being of the connective tissue type (Table 3) .

In

contrast to the situation in human lung, few mast cells were
detected in the rat lung alveolar wall.

In skin, most of

the

mast cells were located in the dermis and in the layer under
the adipose tissue,
tissue type.

and in each case were 81% connective

In the bowel mucosa from fi.

brasiliensis-

infected animals, mucosal (safranin-negative) mast cells were
abundant, accounting for >99% of the mast cells.

Mast cells

obtained by peritoneal lavage accounted for 5-10% of the
cells,

and over 95% were of

the

connective tissue

type

(safranin-positive) .
Tryptase-containing cells also were assessed in lung,
skin bowel and peritoneal cells using goat IgG anti-tryptase
antibody.

No staining was observed using preimmune goat IgG

as a negative control.
abundant

in

lung,

Tryptase-containing cells were most

where

they

were

distributed

in

a
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peribronchial location. Among peritoneal cells they accounted
for only 20% of the cells.

In skin, tryptase-positive cells

were detected in the dermis and below the hypodermis, but at
concentrations that appeared to be less than for mast cells
detected

histochemically.

In

bowel

mucosa

there

were

essentially no tryptase-positive cells.

3. Rat Tryptase Is Localized In Mast Cells
To determine whether tryptase-containing cells were mast
cells and only mast cells, sequential staining with Alcian
blue and anti-tryptase antibody was performed.

For example,

in a section of rat lung, among 4 Alcian blue-stained mast
cells (Figure 13A) , two stained positive for tryptase (Figure
13B) .

In

these

double

labelling

experiments,

the

concentration of mast cells in peribronchial tissue was about
15 x 103 cells/mm3 , 63 ± 8% contained tryptase (Table 3).

In

rat skin, two Alcian blue-positive mast cells are shown in
Figure 13C, one of which stains positive for tryptase (Figure
130).

In general, tryptase-positive mast cells stained less

intensely in skin than in lung.

Tryptase-positive mast cells

accounted for only 7 ± 4% of the 882 ± 136 mast cells/mm3 in
the dermis (Table 3).
the

A cluster of 7 mast cells obtained from
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Figure 13. Sequential Staining With Alcian Blue And AntiTryptase Antibody. Tissue sections from lung (A, B) , skin (C,
D), a cytospin of peritoneal cells (E, F), and bowel (G, H)
were stained first with alcian blue (A, C, E, G) and then with
goat IgG anti-tryptase/peroxidase (brown)
(B, D, F, H).
Identical fields for each cell source are shown.
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G

H

MC/mm3

Cell Source

± SD

(n)
Peribronchus

14,867
± 3966
( 6)

Dermis

47/53 ± 19
(4)

882
136
( 6)

19/81 ± 8

32,264

100/0 ± 0

±

Bowel Mucosa

lSaf ranin"MC
%Safranin+Mc
± SD
(n)

(6)

Tryptase+ x 100 ·
Alcian Blue+
± SD
(n)

Tr.Yfil.flse+ x 100
Safranin+
± SD
(n)

63 ± 8

94 ± 10

(6)

(4)

7 ± 4

6 ± 2

( 6)

(4)

ND

ND

± 22,219

Peritoneal
Cells

(4)

(4)

NA

5/95
( *)

(4)

(4)

19 ± 6

20 ± 8

(12)

(12)

Table 3. Distribution Of Tryptase-Positive Mast Cells.
The results of sequential
alcian blue/tryptase and safranin/tryptase stains are summarized in the table. MC, mast
cell; SD, standard deviation; n, number of tissue sections used; ND, not detectable; NA,
not applicable; *, a total of 80 Safranin"/Alcian Blue+ mast cells among 1600
Safranin+ /Alcian Blue+ mast cells. Areas of tissues examined were 2. 69 mm2 for
peribronchus, 39.9 mm2 for dermis, and 17.0 mm2 for bowel mucosa. Sequential staining
with alcian blue and safranin was used to determine %Safranin· and %Safranin+ mast cells.

~
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N
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peritoneal lavage is shown in Figure 13E,
contain tryptase

(Figure 13F).

three of which

The intensity of tryptase

staining was comparable to mast cells in skin.

Mast cells

accounted for 8% of the total cells, 19% of which contained
tryptase (Table 3).

In rat bowel mucosa from IL.. brasiliensis-

infected animals, essentially none of the mast cells {32,264
± 22,219 cells/mm3 )

(Table 3) that stained blue {Figure 13G),

showed detectable tryptase (Figure 13H) .
not

examined.

The

high

standard

Bowel submucosa was
deviation

for

the

concentration of mast cells in the bowel reflect the uneven
distribution of these mast cells in the cross sections of the
bowel.

Of 591 tryptase-positive cells examined in lung, skin,

and peritoneal lavage cells, all stained with Alcian blue,
implicating mast cells as the major source of this enzyme
among the cells and tissues examined.
Sequential staining with Alcian blue and anti-chymase I
antibody showed that 60% of the Alcian blue cells in lung are
chymase I-positive, over 85% of the Alcian blue cells are
chymase I-positive in skin, 98% of the Alcian blue cells are
chymase I-positive among peritoneal cells and none of the
Alcian blue cells in bowel mucosa were chymase I-positive.

4. Rat Tryptase Resides In The Safranin-Positive CTMC Cells
To determine the distribution of tryptase-positive mast
cells

among

safranin-positive

and

safranin-negative

mast

cells, sequential staining was performed, first with safranin
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and then with anti-rat tryptase.

The results revealed that

all tryptase-positive cells were safranin-positive, but not
all safranin-positive cells contained tryptase.

For lung,

Figure 14A shows 7 safranin-positive mast cells, six of which
contained tryptase (Figure 14B} .

In rat lung, over 90% of the

safranin-positive cells are tryptase-positive (Table 3}.

By

contrast, in skin, 6 safranin-positive mast cells were shown
in Figure 14C, only 1 of which was tryptase-positive (Figure
14D} .

Only about 6% of the safranin-positive cells in skin

contained tryptase (Table 3).

Bowel mucosa lacked safranin

and anti-tryptase stainable cells.

In peritoneal cells,

Figure 14E shows numerous safranin-positive mast cells, most
of

which

contained no detectable

Tryptase-positive cells account

tryptase

(Figure

14F} .

for only 19% of the

rat

peritoneal connective tissue mast cells (Table 3}.

5. Distribution Of Tryptase And Chymase I In Rat Mast Cells
Simultaneous double-labeling experiments were performed
to determine whether tryptase-positive cells are also chymase
I-positive.

Figure 15A shows a section of lung which had 6

blue tryptase-positive cells, all of which
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Figure 14. Sequential Staining With SafraninAndAnti-Tryptase
Antibody.
Tissue sections from lung (A, B) and skin (C, D),
and a cytospin of peritoneal cells (E, F) were stained first
with safranin (red) (A, C, E) and then washed and stained with
goat IgG anti-tryptase/peroxidase (brown) . Identical fields
for each cell source are shown. The red safranin stain was
removed by the washing procedure. All fields are shown under
light microscopy except E, for which phase contrast was used
to show stained mast cells along with unstained cells. This
makes the red cells appear brown.
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became dark brown (Figure lSB), indicating the co-localization
of tryptase and chymase I in these cells. Of the lung mast
cells which contained either tryptase, chymase I, or both, 77%
contained both proteases, 4% contained only tryptase and 19%
contained only chymase

I

(Table

4).

Whether the

small

population of cells (4%) that stained for tryptase and not
chymase

I

truly reflect

chymase

I-negative cells is

not

completely certain, because low levels of staining for chymase
I may not produce sufficient brown staining to overcome the
blue stain from tryptase.

Figure lSC shows a section of skin

which contained one blue tryptase-positive cell that became
brown with the chymase I stain (Figure lSD) .

Among the mast

cells in skin which contained tryptase and chymase I,

9 6%

contained only chymase I, 4% contained both proteases while no
cells contained tryptase only (Table 4) .

Figure lSE shows a

section of peritoneal cells which had one blue tryptasepositive cell that became brown with the chymase I

stain

(Figure lSF) as well as numerous chymase I-positive cells in
which tryptase was not

detected.

Among the mast

cells

containing tryptase and chymase I in peritoneal lavage fluid,
15% contained both protease, 85% contained chymase I alone,
and none contained tryptase without chymase I (Table 4) .
To better ascertain the distribution of two distinct
mast cell types which contain either chymase I or tryptase
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Figure 15. Simultaneous Double Labeling With Anti-Tryptase And
Anti-Chymase I Antibodies. Sections of lung (A, B) and skin
(C,D), and a cytospin of peritoneal cells (E, F) (phase
contrast) were incubated simultaneously with goat IgG antitryptase and rabbit IgG anti-chymase I antibodies. Sections
were developed first with alkaline phosphatase-conjugated
swine anti-goat IgG (blue) (A, C, E) and then with peroxidaseconjugated goat anti-rabbit IgG (brown) (B, D, F). Blue
tryptase-positive cells also containing chymase I turn brown;
Those with tryptase but not chymase I remain blue; Those
containing chymase I and not tryptase would appear brown, and
never blue.
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A

B
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E

F

Cell Source

Cells*

Trmt~se+

x 100
Chymase r+
± SD

Trypta~e+

x 100
Chymase r
± SD

Trmteli!!if x 1QQ
Chymase r+
± SD

(n)
Peribronchus
Dermis
Peritoneal
Cells

45-60
(5)
159-299
(7)
110-300
(12)

77 ± 2

4 ± 2

19 ± 7

4 ± 1

0

96 ± 1

15 ± 2

0

85 ± 3

Table 4. Simultaneous Labeling Of Tryptase And Chymase I. This table shows the results
of the simultaneous double labeling of mast cells with anti-tryptase and anti-chymase I
antibodies. SD, standard deviation; n, number of tissues used in the experiment; *,
number of cells counted per section or slide.

I-'
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in a single section, sequential double-labelling experiments
were performed.

With this technique, deposition of the brown

peroxidase-based stain with the first primary antibody blocks
subsequent staining of those cells with the second primary
antibody linked to alkaline phosphatase. This same phenomenon
has been observed previously for staining of human mast cells
(Irani et al. 1986, 1989}.
tryptase-positive cells.

In lung, Figure 16A shows 2 brown
These cells remain brown while 2

others stain blue with the anti-chymase antibody (Figure 16B} .
By

sequential

staining,

tryptase-positive

cells

in

lung

accounted for 84 ± 7% of the chymase I-positive cells (Table
5).

In skin, a section is shown that contains one tryptase-

positive cell

(Figure 16C} and one chymase I-positive cell

(Figure 16D} .

Tryptase-positive cells in skin account for 7

± 1% of the chymase I-positive cells (Table 5) .

In peritoneal

cells, Figure 16E shows 5 tryptase-positive cells; subsequent
staining with anti-chymase I antibody reveals an additional 9
chymase I-positive cells (Figure 16F} .

About 13 ± 7% of the

chymase I-positive cells in peritoneal lavage fluid are also
tryptase-positive (Table 5).
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Figure 16. Sequential Double Labeling With Anti-Tryptase And
Anti-Chymase I Antibodies. Sections of lung (A, B) and skin
(C, D), and a cytospin of peritoneal cells (E, F} were
incubated first with goat IgG anti-tryptase and developed with
peroxidase-conjugated swine anti-goat IgG (brown) (A, C, E).
Sections and cytospin were then incubated with rabbit IgG
anti-chymase
I
antibody
and developed
with
alkaline
phosphatase-conjugated goat anti-rabbit IgG (blue) (B, D, F).
Cells with tryptase stained brown and remained brown; those
with chymase I became blue only if tryptase was not present.
Panel E was photographed under phase contrast.
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A

B

148

c

D
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•

E

•

F

'

Cell Source

Peribronchus
Dermis
Peritoneal

Cells*
(n)
40-50
(4)
156-412
(4)
105-264
(12)

\Tcyptase+
%-Chymase 1+ **
± SD

-

84/16 ± 7
7/93 ± 9
13/87 ± 7

Table 5. Sequential Labeling Of Tryptase And Chymase I.
The results of sequential
double labeling of mast cells· with anti-tryptase and anti-chymase I are sununarized in
the table. SD, standard deviation; n, number of tissues used in the experiments; *,
number of cells counted per section or slide; **, refers to ChymAse r+/Tryptase· mast
cells.

....
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CHAPTER X
DISCUSSION

Rat Mast Cell Heterogeneity.
Although

rat

tryptase

has

been

purified

from

skin

(Braganza & Simmons 1991) and peritoneal cells (Kido et al.
1985),

its

cellular localization has

determined in this species.

never been formally

In the current study, a goat

polyclonal IgG antibody prepared against purified rat skin
tryptase was used to determine the distribution of tryptase in
rat

skin,

lung,

bowel mucosa and peritoneal

cells.

The

antibody was produced in high titer, as determined by ELISA,
and was specific,

as determined by Western blotting with

extracts from lung, skin and peritoneal cells.

Although the

level of endogenous tryptase (approximately 0.003% of total
protein)

was

exogenously
detected.

too

added

low

for

tryptase,

By

a

detection
but

variety

immunohistochemical

techniques,

exclusively in mast

cells,

but

no
of

by
other

technique,

proteins,

were

histochemical

and

tryptase
only

this

in a

was

localized

subset

of

the

connective tissue type of mast cell.
Localization to mast cells was demonstrated by sequential
staining with alcian blue and anti-tryptase antibody.
the blue mast cells were stained by the antibody.
151

Only

However,

152
although about 50% of mast cells in lung contained tryptase,
most

in skin,

tryptase.

bowel and peritoneal cells did not contain

Before examining the distribution of tryptase among

mucosa! and connective tissue mast cells, the distributions of
these two mast cell types were assessed histochemically, by
sequential staining with alcian blue and safranin.

Mucosa!

mast cells stain blue; mature connective tissue mast cells
stain red.

This sequential staining technique showed that

lung tissue contained similar numbers of both mast cell types.
Skin and peritoneal mast cells were almost exclusively of the
connective tissue type, while those in the bowel mucosa were
almost exclusively of the mucosa! type.
are

similar

Gibson

to

those previously reported

Miller 1986,

&

These distributions

Huntley et al.

(Enerback 1981,

1990).

Sequential

staining with safranin and anti-tryptase antibody,
clarified

the

localization of

tryptase.

in part,

Safranin stains

heparin-containing mast cells, and therefore is a marker of
the mature connective tissue type of mast cell.

Tryptase was

present

not

only

in

safranin-stained

connective tissue mast cells.
tissue.

The

percentage

of

cells,

and 6%

for

skin.

in

all

This varied from tissue to
connective

staining for tryptase was 94% for lung,
cells,

but

Thus,

tissue mast

cells

20% for peritoneal

even though tryptase was

purified from skin, the percentage of mast cells containing
the enzyme in skin is markedly lower than in lung.

The amount

of tryptase in skin mast cells is also lower than that in lung
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mast cells as indicated by weaker tryptase stain in the skin
mast cells.
To confirm localization of tryptase to the connective
tissue

type mast

cells,

double

labeling experiments

were

performed with anti-tryptase and anti-chymase I antibodies.
Mast cell-specific chymases have been chosen to be markers
that distinguish mast cells from other cell types, and mast
cell subsets from one another

(Karger 1990).

In the rat,

chymase I (also called rat mast cell protease I) is found only
in connective tissue mast cells while chymase II (also celled
rat mast cell protease II)
cells

is found only in mucosal mast

(Miller et al. 1990).

Using the simultaneous double

labelling technique, all tryptase-stained mast cells in skin
and peritoneal lavage cells also stained for chymase I.

Only

in lung was there a suggestion that tryptase could reside in
mast cells lacking chymase I.

In this case 4% of tryptase-

stained mast cells did not develop detectable staining for
chymase I by the simultaneous labeling technique.
this

as

an

upper

limit,

because

variations

in

We view
staining

intensity from one cell to the next in tissue sections may
lead to a more intense tryptase stain followed by a

less

intense stain for chymase I which, at the extreme, may not be
detectable by this technique.

Thus, the existence of a minor

population of tryptase-positive, chymase I-negative cells in
lung is questionable.
To more easily determine the distribution of tryptase
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among the connective tissue mast cells, sequential rather than
simultaneous double labelling was used.

Staining with anti-

tryptase antibodies was followed by staining with anti-chymase
I antibodies such that tryptase-positive cells retained the
stain for tryptase (even though they also contained chymase I}
while those negative for tryptase stained for chymase I.

The

percentage of connective tissue mast cells that contained
tryptase by this sequential chymase I technique compared with
the

simultaneous

chymase

I

technique

and

the

sequential

safranin technique were similar: 84, 80 and 94 for lung; 7, 4
and 6 for skin; and 13, 15 and 20 for peritoneal cells.

Thus,

rat tryptase is present in a subset of the connective tissue
type of mast cell.
Our results for tryptase in rat tissues more closely
parallel previously made observations in mouse than in human.
In human,
subset

all mast cells contain tryptase,

contain

chymase

carboxypeptidase and a
Schwartz 1990}.
chymases,

2

(only

one

tissue

chymase

in

cathepsin G-like protease

humans},
(Irani

&

In the mouse, cDNA molecules for at least 5

tryptases

and

1

carboxypeptidase

identified (Reynolds et al. 1990a,
with

whereas only a

extracts

enriched

1990b}.

for mucosa!

have

been

Northern blots
and connective

tissue mast cells suggest that mouse tryptase (MMCP-6}, like
rat tryptase,
whereas

is located in connective tissue mast cells,

chymases

connective tissue

are

distributed

either

mast cell types or both.

in

mucosa!

or
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The

finding that only a subpopulation of connective

tissue mast cells contain tryptase in the rat indicates a
greater

degree

possible

of

heterogeneity

explanation

for

this

than

anticipated.

finding

is

that

expression is pennissible only in connective
cells,
factors.

but
An

is

regulated

and

inducible

by

One

tryptase

tissue mast
environmental

alternative explanation is that there are at

least three distinct subsets of mast cells: tryptase-positive,
chymase I-positive, chymase II-negative; tryptase-negative,
chymase

I-positive,

chymase

II-negative;

and

negative, chymase I-negative, chymase II-positive.

tryptaseFurther

studies will be needed to clarify that to what extent mast
cell heterogeniety is due either to lineage or to environment.
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SUMMARY

Tryptase was purified from rat skin and found to be a
glycoprotein with an apparent molecular weight of about 31, 000
on SDS-PAGE gels.

Incubation of the enzyme with N-glycanase

converted the enzyme from a broad band to a sharp single band
with a molecular weight of approximately 27,000.

The amino

acid sequences of the N-terminus, four tryptic peptides, and
one lysylendopeptidase-C peptide were determined by the Edman
procedure.

These sequences accounted for 119 amino acids or

about 45% of the total primary structure.

The peptides have

an overall 81-82% identity to human tryptases,

75% to dog

tryptase, 77% to mouse tryptase-1, 93% to mouse tryptase-2,
and 43% to bovine trypsin.

Among the peptides sequenced are

the active site region containing the catalytic serine residue
and

the

substrate-binding

aspartate.

glycosylation sites have been identified.
highly conserved among tryptases.

Two

One of them is

The other only appears in

mouse tryptase-2 but not the other tryptases.
five

putative

Four of the

tryptophan residues unique to tryptases but not

trypsin were found in the peptide sequences.

to

The results

revealed considerable structural differences between tryptase
and trypsin as well as some significant structural variations
among tryptases.

This work has provided a solid support for

future

on

studies

the

correlation

of

the

functional

characteristics of tryptases to their structural properties.
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The cellular distribution of rat tryptase was examined in
rat skin, lung, small intestine and peritoneal lavage cells by
immunohistochemical techniques. Tryptase purified to apparent
homogeneity from rat skin was used to generate goat polyclonal
anti-rat tryptase antibody.

Western blotting of extracts of

skin, lung and peritoneal cells showed that the antibody was
specific for rat tryptase.

Tryptase containing cells were

detected in lung, skin, and peritoneal lavage cells.

Small

intestinal mucosa, on the other hand, was found to have few,
if any, tryptase-positive cells.

Sequential staining with

alcian blue and anti-tryptase antibody showed that tryptase
was located only in mast cells.

Sequential staining with

safranin to identify the connective tissue type of mast cell,
and anti-tryptase antibody showed that tryptase resides only
in this mast cell type.

However, only a subpopulation of the

safranin-positive mast cells contained tryptase.

In lung, 53%

of the mast cells stained with safranin, and 94% of these were
tryptase-positive.

In skin, 80% of the mast cells stained

with safranin, but only 6% of these were tryptase-positive.
In peritoneal cells, more than 95% of the mast cells were
safranin-positive,
positive.

but

onle

20%

of

these

were

tryptase-

In the bowel mucosa, where few safranin-positive

cells exist, no tryptase-positive cells were detected.

The

simultaneous and sequential double-labeling with anti-tryptase
and anti-chymase I antibodies were performed to confirm and
extend the histochemical findings.

The percentages of chymase
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I-positive

cells

that

were

tryptase-positive

by

the

simultaneous and sequential techniques, respectively, were 80
and 84

for lung,

peritoneal cells.

4 and 7 for skin,

and 15 and 13

for

The data from our study suggest that the

rat connective tissue type of mast cell is subdivided into two
forms based on the presence or absence of tryptase.
mucosa! mast

cells are devoid of

although it is possible that a

Rat

skin-derived tryptase,

tryptase could reside in

mucosal mast cells that lacks immunological crossreactivity.
These results contrast with those in humans, where tryptase is
present in all mast cells.

However, the results are similar

to those in the mouse, where tryptase mRNA has been detected
only in the connective tissue type.

APPENDIX
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APPENDIX A: ENZYME PURIFICATION SOLUTIONS

Homogenization Buffer:
Dissolve 9.29 g of sodium phosphate monobasic, 43.9 g of
sodium phosphate dibasic, 6.27 g of EDTA, and 438 g of
NaCl in 15 1 of Milli Q {MQ)

water.

The solution

contains 25 mM of sodium phosphate, 1 mM EDTA, and 0.5 M
of NaCl, pH 7.

Dialysis Buffer:
Dissolve 69 g of sodium phosphate monobasic, 8.3 g of
EDTA, and 584.4 g of NaCl in MQ water; adjust to pH 6,
and bring the volume to 20 1 with MQ water.

The solution

contains 25 mM of sodium phosphate, 1 mM of EDTA, and 0. 5
M of NaCl.

PAB

Wash Buffer:

Dissolve

14.6

g

of

NaCl,

and

240.4

g

of

urea

homogenization buffer to a final volume of 500 ml.
final solution contains 25 mM sodium phosphate,
EDTA, 1 M NaCl, and 8 M urea, pH 7.
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PAB Equilibration Buffer:
Dissolve 3.45 g of sodium phosphate monobasic, 0.2 g of
NaN3 , and 29.2 g of NaCl, adjust to pH 6, and bring the
volume to 1 1 in MQ water.

The final solution contains

25 rnM of sodium phosphate,

O. 5 M of NaCl,

and

o. 02%'

(w/v) of NaN3 •

PAB Elution Buffer:
Dissolve 1566 mg of benzarnidine in 100 ml of the PAB
equilibration buffer.
sodium phosphate,

The final solution contains 25 rnM

0.5 M NaCl,

0.02%' NaN3 ,

and 0.1 M

benzarnidine, pH 6.

Con-A Activation Buffer:
Dissolve 6.8 g of sodium acetate, 10.2 g MgC1 2 , 29.2 g of
NaCl, 555 mg of CaC1 2 , and 100 mg of NaN3 ; adjust to pH 6,
and bring to 500 ml in MQ water.

The final solution

contains 100 mM of sodium acetate, 100 rnM of MgC1 2 , 1 M
of NaCl, 10 mM of CaC1 2 , and 0.02%' of NaN3 •

Con-A Elution Buffer:
Dissolve 10 g of

~-methyl-D-rnannoside

PAB equilibration buffer.

in 100 ml of the

The final solution contains 25

rnM of sodium phosphate, 0.5 M of NaCl, 0.02%' of NaN3 , and
100 mg/ml of the rnannoside, pH 6.
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Con-A Wash Buffer:
Dissolve 987.5 mg of Tris-HCl, and 168 mg of EDTA in MQ
water; adjust to pH 6, and bring the volume to 250 ml.
The final solution contains 25

mM

Tris-HCl, and 2

mM

EDTA.

Enzyme Assay Buffer:
Dissolve 709.8 mg of sodium phosphate dibasic and 67.2 mg
of EDTA in MQ water; adjust to pH 7.5, and bring the
volume to 200 ml.
phosphate and 1

10

mM

mM

The solution contains 25

mM

sodium

of EDTA.

BAEE Solution:

Dissolve 17.14 mg of BAEE in 5 ml of MQ water; stored at
4 °C.

APPENDIX B. SDS-PAGE SOLUTIONS

Sample Buffer:
The solution contains 2. St of SDS

(2S µl

of 2ot SDS

stock), 10 mM of Tris and 1 mM EDTA (0.1 ml of 20 mM
Tris, 2 mM EDTA), o.s mM DTT (lS µl of 10 mM/ml DTT), and
O.Olt of Bromophenol Blue (2 µl of lt Bromophenol Blue).

sot Ethanol, lOt Acetic Acid:

Mix SO ml of lOOt ethanol with 40 ml MQ water, then add
10 ml of acetic acid.

lOt Ethanol, St Acetic Acid:

Mix SO ml of lOOt ethanol with 42S ml water, then add 2S
ml acetic acid.

8.3t Glutaraldehyde:

Mix 40 ml of the 2St commercial glutaraldehyde with 80 ml
of MQ water.

0.2S% Silver Nitrate:

Desolve 2SO mg of silver nitrate in 100 ml MQ water. Make
163
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this solution fresh.

Developer:
12. 5% Na2C03 stock: Disolve 25 g of Na2C03 in 200 ml of MQ
water. Prior to the experiment, mix so ml of the 12.5%
Na2C03 stock with 200 ml of MQ water.

5% Acetic Acid (v/v) :
Add 5 ml of acetic acid to 95 ml of MQ water.

10%

Acetic Acid, 6% Glycerol (v/v) :

Desolve 6 ml of glycerol in 84 ml of MQ water; add 10 ml
of acetic acid.

APPENDIX C: ALKYLATION SOLUTIONS

Tris-HCl Buffer:
Dissolve 18.17 g of Tris-Base and 500 mg of EDTA in MQ
water;

adjust to pH 8. 6 and bring to 100 ml.

The

solution contains 1.5 M Tris and 5 mg/ml EDTA.

Iodo- [3H] Acetic Acid Solution:
Dissolve 1 mCi of the iodo[2- 3H]acetic acid in 0.1 ml of
MQ water to give a 0.1 mCi/ml solution.

The specific

activity was 175 mCi/mmol.

Cold Iodoacetic Acid Solution:
Dissolve 14.5 mg of iodoacetic acid in 108 µl of 0.5 N
NaOH to 134 mg/ml.

6 N HCl Solution:

Add 500 µl of the concentrated HCl slowly to 500 µl of MQ
water under the hood.

100 mM Ammonium Bicarbonate Buffer:

Dissolve 3.95 g of NH4HC03 in 500 ml MQ water and adjust
to pH 8.
165
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9% Formic Acid:
Mix 51 ml of the 88% formic acid stock with 449 ml of MQ
water.

APPENDIX D: WESTERN BLOT SOLUTIONS

Homogenization Buffer:
Dissolve 976 mg of MES and 14.5 g of NaCl in MQ water;
adjust to pH 6 and bring to a final volume of 500 ml with
water.

The solution contains 10 mM MES and 0.5 M NaCl.

Chymase Assay Buffer:
Dissolve 960 mg of Tris-Base and 1.47 g of CaC1 2 , adjust
to pH 7. 8 and bring to 500 ml with MQ water.

The

solution contains 80 mM Tris and 100 mM CaC1 2 •

1 mM BTEE {N-Benzoyl-L-Tyrosine Ethyl Ester) :
Dissolve 16.8 mg of BTEE in 25 ml of methanol and bring
the volume to 50 ml with MQ water.

20% TCA:
Mix 0. 8 ml of trichloroacetic acid with 3. 2 ml of MQ
water.

Staining Solution:
Dissolve 1 PhastGel Blue R tablet in 80 ml of MQ water;
stir for 10-15 minutes;

add 120 ml of methanol;
167

stir
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again for 2 minutes, and then filter the solution which
contains 0.2% PhastGel Blue R.
Mix 10 ml of the 0.2% PhastGel Blue R with 90 ml of 20%
acetic acid.

Destaining Solution (30% Methanol and 10% Acetic Acid):
Add 90 ml of methanol to 180 ml of MQ water; add 30 ml of
acetic acid to the above.

Preservative Solution (5% Glycerol and 10% Acetic Acid) :
Mix 5 ml of glycerol with 85 ml of MQ water; add 10 ml of
acetic acid.

PhastTransfer Buffer:
Dissolve 1.5 g Tris-Base and 7.2 g glycine in 400 ml of
MQ water; add 100 ml of methanol.
25

mM

The solution contains

Tris, 192 mM of glycine, and 20% methanol, pH 8.3.

10 X TBS:
Dissolve 6 g of Tris-Base and 43.5 g of NaCl; adjust to
pH 7.5 and bring the volume to 500 ml with MQ water.

1 X TBS:

Make a 1:10 dilution from the 10 X TBS solution with MQ
water.
mM

The final solution contains 10

NaCl, pH 7.5.

mM

of Tris and SO
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Blocking Buffer (3% BSA/TBS) :
Dissolve 3 g of bovine serum albumin, fraction V in 100
ml of the 1 X TBS.

0.5% BSA/TBS:
Dissolve 0.5 g of BSA in 100 ml of the 1 X TBS.

Second Antibody Solution:
Dilute 15 µl of the peroxidase or alkaline phosphatase
conjugated secondary antibody in 15 ml
BSA/TBS.

AEC/~02

Solution:

See appendix F.

of

the

o. 5%

APPENDIX E: TISSUE SECTION PREPARATION

Carney's Solution:
In a bottle, mix 60 ml of 100% ethanol, 30 ml chloroform,
and 10 ml glacial acetic acid.
°C.

The final

Store the solution at 4

solution contain s

60%

ethanol,

30%

chloroform, and 10% acetic acid.

PBS (Phosphate Balanced Saline) :
Dissolve 8 g of NaCl, O. 2 g of KCl, 1. 44 g of Na2HP04 and
0.24 g

K~P04

in 800 ml of MQ water; adjust to pH 7.4 with

HCl and add water to 1 liter.

PBS/Heparin Buffer:
Dissolve 80 mg of gelatin in 80 ml of PBS by stirring on
a hot plate; cool the solution to room temperature; add
0.8 ml of 1000 U/ml of heparin.

PBS/DNase Buffer:
Dissolve 10 mg of gelatin in 10 ml of PBS by stirring on
a hot plate; cool the solution to room temperature; add
10 µl of DNase at 10 mg/ml.
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~0 2 /Methanol

Solution:

Add O. 8 ml of 30%

~02

to 40 ml of methanol.

which contains 0.6% of
the reaction.

~0 2

The solution

in methanol was made prior to

APPENDIX F: IMMUNOHISTOCHEMICAL STAINING

0.5% Alcian Blue Solution:
Dissolve 0.5 g of alcian blue 8 GX in 100 ml of MQ water
by stirring; adjust to pH 1 with concentrated HCl; filter

through a No. 4 filter from Millopore.

The solution is

stable for a few months at room temperature.

0.1% Safranin O Solution:
Add 1 ml of glacial acetic acid to 99 ml of MQ water;
dissolve 0.1 g of safranin O in 100 ml of the 1% acetic
acid solution.

The solution is stable for a few months

at room telnperature.

PBS/BSA Solution:
Dissolve 1 g of bovine serum albumin fraction V and 10 mg
of thimersol in 100 ml of BSA {appendix E); store the
solution at 4 °C.

TTBS:
Dissolve

24

g

of

Tris-Base,

36

g

of

NaCl,

0.4

g

thimersol, and 2 ml of Tween-20; adjust to pH 7.4; bring
to 4 1 with MQ water; store in 500 ml aliquot at 4 °C.
172

173
AEC/~02

Solution:

O.1 M acetic acid solution:
acetic

acid

in 100 ml

of

dissolve 2.72 g of sodium

Add 1.16 ml of glacial
MQ water

acetate.3~0

for

solution A;

in 100 ml of MQ

water for solution B. Mix 14.8 ml of solution A with 3S.2
ml of solution Band SO ml of MQ water; adjust to pH S.2
to render a 0.1 M acetic acid solution.
AEC

solution:

Dissolve

20

mg

of

3-amino-9-

ethylcarbazole in S ml of N-N-dimethylformimide; add 100
ml

of

the

O.1 M acetic acid solution;

stir at

room

temperature for S minutes; filter the solution through a
0.45 µm membrane; store the AEC in 1 ml aliquot at -20

oc.
Mix 29 ml MQ water with 1 ml of the 30%
commercial

~0 2

stock.

The AEC/H20 2 solution is prepared prior to the reaction by
adding 10 µl of the 1%

~0 2

to the 1 ml AEC.

DAB/H20 2 Solution:
DAB solution:

Dissolve 3 g of Tris-Base in SOO ml MQ

water; adjust to pH 7.6 with HCl to form a O.OS M Tris
buffer; dissolve 5 mg of diaminobenzidine in 10 ml of the
O. OS

M Tris buffer;

stir at

room temperature

for

S

minutes; filter through a 0.4S µm membrane.
1%

~0 2 :

commercial

Mix 29 ml MQ water with 1 ml of the 30%
~0 2

stick.
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Add 10 µl of the 1%
DAB/~02

~02

to 1 ml of the DAB solution. The

solution must be prepared fresh every time prior

to the reaction.

Naphthol/Fast Blue Solution:
0.1 M Tris buffer:

Dissolve 6.05 g of Tris-Base in 500

ml of MQ water; adjust to pH 8.2; store at 4 °C.

Prior to the reaction, dissolve 5 mg of naphthol AS-MX in
0.5 ml of N,N-dimethylformimide; add 24.5 ml of the 0.1

M Tris buffer warmed to 37 °C; add 6 mg of levarnisole;
dissolve 5-10 mg of Fast Blue RR in the above solution to
1

mg/ml;

minutes.

filter

and use

the

solution within 20-30
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